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Background 
It is well accepted that phenobarbitone (PHB) requires therapeutic drug monitoring (TDM).  
The conventional matrix of serum or plasma used for TDM of phenobarbitone is not easily, 
cheaply or safely transported long distances. An alternative is to measure phenobarbitone in 
dried blood spots (DBS). These are stable and easily transported.  This provides an affordable 
and safe alternative for rural hospitals in India. 
Objectives 
To determine if the concentration of phenobarbitone in serum can be accurately predicted 
either directly or with an equation from that measured in dried blood spots. 
Methods 
Thirty six patients between (and including) the ages of 18 to 65, who were on 
phenobarbitone, were enrolled into the study after informed consent was obtained. The DBS 
specimens were prepared by spotting 20µl of whole blood on a standard Whatman filter 
paper using a calibrated micropipette. Separate validated High Performance Liquid 
Chromatography (HPLC) assays were used to measure the concentration of phenobarbitone 
in serum and DBS. Normal distribution was assessed, precision and bias were calculated 
along with regression using the Spearman rank correlation test and the Mann Whitney-U 
paired test was performed.  
Results 
The imprecision and the bias between the measured and the predicted serum concentrations, 
when corrected for haematocrit were 8% and 0.49% respectively. The data were not normally 
distributed. The correlation coefficient was 0.99 between the serum and corrected dried blood 
spot (CDBS) concentrations (Spearman rank correlation test). No statistical difference was 
found between the two groups by the Mann Whitney-U test (p=0.3919).   
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Conclusion  
The concentration of phenobarbitone in serum can be accurately predicted directly from that 
measured in a DBS. This means that a simple, cheap, easily accessible dried blood spot TDM 
service is available for rural hospitals in India. 
Keywords 
Dried blood spot, phenobarbitone, serum, TDM 
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A large number of people around the world are affected by epilepsy. The burden of epilepsy 
is higher in the developing than developed countries. Upto 70% of the people respond to 
treatment if adequately treated. Phenobarbitone is the most widely prescribed antiepileptic 
drug worldwide because of its low cost, good efficacy and convenient dosing of once daily.  
 
Therapeutic drug monitoring is a common tool used to optimise drug therapy by 
individualising the dose of the drug.  Antiepileptic drugs are commonly subjected to TDM 
due to inter-individual variability in its pharmacokinetics, numerous drug interactions being 
potent enzyme inducers or inhibitors and the non-linear relationship between the dose and the 
serum/plasma concentration of the drug. It is well accepted that phenobarbitone requires 
therapeutic drug monitoring.  
 
The standard matrix for measuring drug concentration is serum/plasma. The conventional 
serum or plasma samples used to measure phenobarbitone pose two problems. The first is 
that, it cannot be easily transported, and in order to be sent from a rural hospital to a 
therapeutic drug monitoring facility would require cold chain conditions, thereby increasing 
the cost of transport. Secondly, the specimens being transported as whole blood, plasma or 
serum increase the risk of biohazard to handlers.  A relatively newer technique which is 
becoming more common is the use of the dried blood spot. These specimens have the 
advantage of being stable and less infectious, and hence can be easily and cheaply transported 
by regular mail for analysis to a TDM facility.  
 
This study was done to determine if the concentration of phenobarbitone in serum can be 
accurately predicted from a DBS specimen. This will open avenues for these specimens to be 
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used as a safer and cheaper alternative for rural hospitals to send blood for phenobarbitone 
monitoring. 
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Aim 
To determine if the concentration of phenobarbitone in serum can be accurately predicted 
from that measured in dried blood spot and to determine if any equation needs to be applied 
to the DBS result to obtain the serum concentration. 
 
Objectives 
1. To develop and validate a High Performance Liquid Chromatography (HPLC) assay 
to measure the concentration of phenobarbitone in serum. 
2. To develop and validate a HPLC assay to measure the concentration of 
phenobarbitone in dried blood spot. 
3. To measure the concentration of phenobarbitone in serum, using HPLC.  
4. To measure the concentration of phenobarbitone in dried blood spot specimens 
obtained on standard Whatman filter paper, using HPLC. 
5. To determine the correlation between phenobarbitone concentration in serum and 
DBS. 
6. To determine if any equation needs to be applied to the dried blood spot result to 
obtain the serum concentration. 
7. To determine the precision and the bias of the equation in predicting the serum 
concentration of phenobarbitone using an independent group of patients. 
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Burden of neurological disorders 
Neurological disorders are an important cause of mortality and morbidity worldwide (1). 
Most of these disorders occur more commonly in the developing countries and many of them 
are both preventable and treatable (1). Epilepsy comes under the category of serious 
neurological disorders (2). There is a two to three times increased risk of dying prematurely 
in people with epilepsy than in a general population (3). 
Burden of epilepsy  
According to WHO, epilepsy accounts for 0.5% of the global disease burden (4). 50 million 
people around the world are affected by epilepsy  (3).  
With more than 85% of the people with epilepsy being present in the developing countries, 
epilepsy is much more common in the developing than the developed world (5). The seizures 
in upto 70% of epileptic patients can be completely controlled (3). Yet, in the developing 
countries, upto three fourth of the epileptic patients either do not receive any treatment or 
receive inadequate treatment (3). This is because of multiple social, economic and political 
barriers such as social stigma, limited availability of resources and the high cost of newer 
drugs (6).  
There are not many epidemiological studies done on the burden of epilepsy in India. A  
recent meta-analysis showed an overall prevalence of 5.33 per 1000 (7).  The number of 
Indian people with epilepsy was estimated to be 5.5 million in the year 2001 (7). The 
incidence was found to be 49.3 per 1,00,000 population (8,9), thus giving rise to half a 
million new cases every year. In India, the treatment gap in epileptic patients is found to be as 
high as 50-70% (10). The reasons for this include the high cost of drugs, misconceptions 
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about the disease leading to faulty practices, failure to identify patients with epilepsy and 
unavailability of treatment to patients (11). 
Epilepsy 
The  International League  Against  Epilepsy (ILAE) and  the  International  Bureau  For 
Epilepsy (IBE) has defined epilepsy as “ A  disorder  of  the  brain  characterized  by  an  
enduring  predisposition  to  develop  epileptic  seizures  and  by  the  neurobiologic,  
cognitive,  psychological,  and  social  consequences  of  this  condition  ” (12). An epileptic 
seizure is characterised by abnormal excessive brain neuronal activity resulting in the 
transient  clinical manifestations (12).  
Etiological classification of epilepsy 
Classification of both epilepsy and seizures are important for its proper management. 
Identification of the type of seizure is important for selecting the appropriate drug for that 
particular seizure as well as to focus on the diagnostics relevant to the possible aetiologies 
(13). 
 The International League Against Epilepsy has classified epilepsy on the basis of aetiology, 
into idiopathic, symptomatic, provoked and cryptogenic epilepsies (14). Idiopathic epilepsy is 
mainly genetic in origin and  there is no gross abnormality, anatomically or pathologically 
(14). An example of idiopathic epilepsy is generalised epilepsy with febrile seizures (14). 
Symptomatic epilepsy can have a genetic or an acquired origin. There are gross 
abnormalities, anatomically and pathologically, and the person will have the signs and 
symptoms of the underlying disease condition which is causing the epilepsy (14). Examples 
of genetic or developmental causes resulting in symptomatic epilepsy are Down’s syndrome 
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and Tuberous sclerosis (14). A few acquired causes include cerebral tumours, cerebral 
trauma, cerebral infections, cerebrovascular disorders and cerebral immunogenic conditions 
like systemic lupus erythematosus (14). In provoked epilepsy, the seizures are precipitated by 
some systemic or environmental factor like fever, drugs, alcohol or toxins (14). There are no 
gross neuro-abnormalities – anatomically or pathologically (14). Reflex epilepsies are a type 
of provoked epilepsy which is induced by factors like loud noise, light or hot water (14). 
Cryptogenic epilepsy is one in which the cause of the epilepsy is not known. It accounts for a 
minimum of 40% of all the epilepsies seen in the adult population (14). 
Classification of seizures 
The ILAE Commission on Classification and Terminology (2011-2013) provided an updated 
classification of seizures (15). Seizures were classified into generalised, focal and unknown 
seizures (15). Generalised seizures were further classified into tonic-clonic, myoclonic, 
absence, tonic, clonic and atonic seizures (15). While generalised seizures involve both the 
cerebral hemispheres, focal seizures typically involve only one cerebral hemisphere (13). 
However, focal seizures can evolve and become generalised in nature and the focus of such a 
seizure is usually in the frontal lobe (13). Unknown seizures are those which do not show 
enough features to classify them under either generalised or focal seizures (15).  
Status epilepticus 
Status epilepticus is a condition in which a single seizure lasts for a duration of more than 30 
minutes or two or more seizures occur without attainment of consciousness in between (16). 
It is a commonly encountered medical emergency and is associated with high morbidity and 
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mortality (17). When status epilepticus does not respond to the standard treatment , it is said 
to be refractory in nature and is associated with even greater mortality (17).  
A history of pre-existing epilepsy is commonly seen in these patients. In such patients, the 
mechanism for status epilepticus is a sharp fall in the serum concentration of antiepileptic 
drugs due to factors like noncompliance to treatment (17). 
Mechanisms in the initiation and spread of seizure activity 
There are two phases involved in this (13) : 
a. Seizure initiation phase 
b. Seizure propagation phase 
Seizure initiation phase (13) 
This phase starts with a burst of action potentials or repetitive action potentials. These action 
potentials are fired at a high frequency. The repetitive action potentials are due to prolonged 
depolarization of the neuronal membrane. Prolonged depolarization occurs due to the entry of 
sodium (Na+) ions into the cell through the voltage gated sodium channels. This is followed 
by hyperpolarization caused by the action of the inhibitory neurotransmitter, ɣ-amino butyric 
acid (GABA) or through potassium (K+) channels.  
Seizure propagation phase (13) 
The seizure activity is propagated by recruiting the surrounding neurons. The surrounding 
neurons get activated by the following mechanisms: 
1) The extracellular potassium increases. This weakens the hyperpolarization and causes 
depolarization of the surrounding neurons. 
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2) In the presynaptic terminals, calcium increases. This increases the release of 
neurotransmitters. 
3) The excitatory neurotransmitter, N-methyl-D-aspartate (NMDA) activates the NMDA 
receptor. This causes the inflow the calcium into the cell and activates the neurons. 
When sufficient number of neurons is recruited from the surrounding area, the seizure 
activity will spread to other contagious areas. 
Drugs used in the treatment of epilepsy 
There are numerous drugs available for the treatment of epilepsy. Choosing the appropriate 
drug according to the seizure type is important. 
According to the ILAE guidelines for the treatment of epileptic seizures, the choice of an 
antiepileptic drug should be individualised (18). In addition to the efficacy of the drug, the 
physician should also take into consideration other factors such as drug safety and 
tolerability, formulation, pharmacokinetics and cost of the drug while choosing a drug to treat 
a newly diagnosed or untreated epileptic patient (19).  
Table 1 shows the numerous drugs used in the treatment of epilepsy with their mechanisms of 
action. 
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Table 1  : Antiepileptic drugs with their mechanism of action (20) 
 
S.no. Mechanism of action Antiepileptic drug 
1 
Sodium Channel modulators,  
Stabilize the fast inactivated state 
Phenytoin, Carbamazepine, 
Lamotrigine, Oxcarbazepine, 
Topiramate, Valproate 
2 
                  Sodium Channel modulators,   
              Stabilize the slow inactivated state 
Lacosamide 
3 
Calcium channel blockers,  
Block high voltage P/Q type channel 
Gabapentin, Pregabalin 
4 
Calcium channel blockers,  
Block T type channel  
Ethosuximide 
5 GABAA receptor allosteric modulators 
Benzodiazepines, Phenobarbitone, 
Topiramate, Carbamazepine, 
Oxcarbazepine 
6 GABA transaminase inhibitors Vigabatrin 
7 NMDA receptor antagonists Felbamate 
8 AMPA/kainate receptor antagonists Phenobarbitone, Topiramate 
9 Enhancers of HCN channel activity Lamotrigine 
10 SV2A protein ligand Levetiracetam 
11 Brain carbonic anhydrase inhibitors 
Acetazolamide, Topiramate, 
Zonisamide 
 
 
 
18 
 
Carbon atom at position 5 
Phenobarbitone 
Introduction 
Chemically known as 5-ethyl-5-phenyl barbituric acid,  phenobarbitone  is  one  of  the  
oldest anti-epileptic  drugs  which is still available in the market (21).  It’s  anti-epileptic  
properties  were  accidentally  discovered  in  the  year  1912,  when a young doctor named 
Alfred Hauptmann found  that it decreased seizures when  given  as  a  sedative  in  a  patient 
with  epilepsy (21).  Phenobarbitone is a long acting barbiturate and became the second drug 
in its class to be clinically used after barbital (21).  
Being  the  most  cost-effective  anti-epileptic  drug, makes  phenobarbitone  the  most  
widely  prescribed  anti-epileptic drug in  the  developing  world  (21). Its cost-effective 
nature enables it to play an important role in reducing the treatment gap in the developing 
countries (21). 
 
Structure 
Phenobarbitone has a molecular weight of 232.23. It is denoted by the molecular formula C12 
H12N2O3 (22). 
Figure1:Structure of phenobarbitone (Reference: http://pubchem.ncbi.nlm.nih.gov/summary) 
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Structure – activity relationship 
Barbiturates have two substituents attached to the carbon atom at position 5 (Figure 1) (20). 
For phenobarbitone, one of the substituents is a phenyl group (Figure 1) (20). The 
substitution with the phenyl group gives it maximum anti-seizure activity (20). 
 
Mechanism of action  
Phenobarbitone is a general CNS depressant (20). It has numerous mechanisms of action, but 
it acts mainly through the inhibitory neurotransmitter GABA, and increases the inhibition at 
the synapse (20). Normally, GABA binds to the GABAA receptor chloride channel complex, 
which is a post synaptic receptor (20). Activation of the GABAA receptor causes opening of 
the chloride channel, resulting in hyperpolarization of the post-synaptic membrane (20). This 
reduces the continuous firing of the neurons seen in a seizure. 
GABAA receptor is a ligand gated ion channel complex and is made up of 2 α, 2 β and 1 ɣ  
subunits (23). Barbiturates act by binding to an allosteric site on the GABAA receptor called 
the “barbiturate binding site” which is different from the binding site of GABA (23).  
Following are the numerous mechanisms involved in the action of phenobarbitone: 
1. It increases the binding of  GABA to the GABAA receptor (20). 
2. It increases the action of GABA on GABAA receptor. This increases the duration that 
the chloride channels remain open,  but does not increase the frequency of opening of 
the channels (20). 
3. At higher concentrations, it causes direct activation of the GABAA receptor and does 
not require GABA for its action(20) .  
Thus, phenobarbitone has both GABA-facilitatory and GABA-mimetic actions. 
4. It blocks the AMPA subtype of glutamate receptors and decreases the depolarization 
caused by glutamate (20). 
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5. It blocks the P/Q type of calcium channels located pre-synaptically and decreases the 
release of excitatory neurotransmitters like glutamate (23). 
 
Figure 2: Mechanism of action of phenobarbitone 
 
Efficacy of phenobarbitone as an antiepileptic drug 
Systemic reviews and meta-analysis comparing the efficacy of phenobarbitone to phenytoin 
and carbamazepine have shown that phenobarbitone is as efficacious as either of the drugs in 
the treatment of both the first episode of seizures as well as in epilepsy which is established 
(24). Currently, the WHO recommends phenobarbitone as the first line drug in both adults 
and children with epilepsy in the developing countries (24). This is because of the low cost 
Source: Brunton LL, Chabner BA, Knolmann BC: 
Goodman and Gilman’s The Pharmacological Basis of 
Therapeutics, 12th edition, www.accessmedicine.com 
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and good efficacy of the drug (24). It is included in the WHO’s essential drug list  as well as 
in the national essential drug list of majority of the responding countries (24).  
Inspite of being in use as an antiepileptic drug for over a century, not many randomised 
control trials have been done to evaluate the efficacy of the drug (24). One of the main 
reasons was this is the low cost of the drug which has diminished the interest taken by the 
pharmaceutical companies in funding any further research (24). There are no clinical trials 
comparing phenobarbitone with valproate or any of the newer antiepileptic drugs (24). 
However, several observational studies conducted mostly in the developing countries have 
provided adequate evidence for its efficacy (24).  
 
Uses  
Phenobarbitone has a broad spectrum efficacy. It is used in the treatment of partial and 
various types of generalised seizures except absence seizures (25) . It is efficacious in  the 
treatment of status epilepticus, idiopathic generalised epilepsy which is refractory to 
treatment and intractable secondarily generalised epilepsy syndromes (24). It is used as first 
line therapy in status epilepticus resistant to benzodiazepines and is the drug of choice in 
neonatal seizures (24). 
 
Adverse effects 
Neurotoxicity caused by phenobarbitone is an important concern. Sedation and drowsiness 
are the most common side effects reported by patients on phenobarbitone (24). However, 
usually patients become tolerant to the effect after a period of time (26).  
Other adverse effects affecting the nervous system include ataxia, nystagmus, hypotonia, 
diplopia, and dizziness (13,24). An adverse effect of concern seen in children is the 
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paradoxical excitation with irritability and hyperactivity (24).  In the elderly, it can produce 
agitation and confusion (20).  
Impairment of cognition and depressed mood and affect are the other major concerns with 
phenobarbitone (27). The more uncommon side effects include megaloblastic anaemia, 
osteomalacia, hypersensitivity, exfoliative dermatitis and agranulocytosis (24,27).  
Adverse effects like sedation are seen when the serum concentration of phenobarbitone 
gradually rises from 30 mg/l to 50 mg/l (28). Concentrations above 60 mg/l can result in 
severe toxicity (20). Children can show severe behavioural abnormalities in the absence of 
other signs of severe toxicity. Hence, children should not be maintained on very high doses of 
phenobarbitone. Only if the seizures are not controlled and the drug is well tolerated, should 
the concentration of phenobarbitone be increased above 30-40 mg/l (20) 
 
Pharmacokinetics  
When given orally, phenobarbitone gets absorbed almost completely (bioavailability of 95- 
100%). However, the absorption is slow and peak levels are attained in serum several hours 
after a dose (20). Its plasma protein binding is between 40-60% (20).  
While upto 25% of the drug gets eliminated renally in the unchanged form, the remaining 
drug is metabolised in the liver, partly by oxidation and partly by N-glucosidation (26) . 
Oxidation takes place with the help of the Cytochrome P450 (CYP 450) enzymes (20). 
Phenobarbitone gets metabolised mainly by the CYP2C9, and to a lesser extent by the 
CYP2C19 and CYP2E1 isoenzymes (20). During metabolism, the radicals located at C5 will 
get oxidised to terminate the activity of the drug (20). Metabolism by the hepatic enzymes 
gives rise to alcohols, acids and ketones, which are eliminated in urine as glucuronide 
conjugates (29). The rate of metabolism of phenobarbitone in the liver is generally slow (29).  
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The concentration of phenobarbitone in the brain correlates well with the unbound serum 
concentration (27). Phenobarbitone exhibits linear kinetics i.e. the serum concentration 
increases linearly with the dose (26). 
It has a long elimination half-life of 4-5 days (29), which enables it to be dosed once daily 
(27). Being a weak acid with a pKa of 7.4, its elimination in urine can be enhanced by 
alkalinizing the urine (29). Alkalinisation increases the ionization of the drug in urine and 
decreases its reabsorption from the ultra-filtrate(29). 
Both oral and parenteral formulations of the drug are available. 
 
Pharmacokinetic variability 
Phenobarbitone exhibits considerable inter-patient variability with regard to different 
pharmacokinetic parameters.  
Absorption 
When given orally in adults, phenobarbitone gets absorbed relatively rapidly (mean Tmax  = 
0.5 - 4 hours) , with a bioavailability of nearly 100% (30,31). On the other hand, neonates 
when given phenobarbitone orally, show delayed (Tmax = 1.5 – 6 hours) and incomplete 
absorption (32).  
Volume of distribution and protein binding 
The volume of distribution of phenobarbitone in adults is 0.54 – 0.73 L/kg with a protein 
binding of 50 - 60% (30,31). This is similar to the volume of distribution seen in older infants 
and children (0.57 – 0.70 L/kg) (32,33). Neonates and younger infants show a higher volume 
of distribution (0.71 – 1.17 L/kg) with lower protein binding (36 - 43% in neonates) (34–37).  
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Elimination in the unchanged form  
Normally, about 25% of the drug is eliminated via the kidneys in the unchanged form, while 
the remaining is metabolised in the liver (20). However, there is considerable inter-patient 
variability with regard to this (38,39).  
Half life 
The half-life of phenobarbitone varies significantly with age. The half-life decreases 
gradually  from 114.2 ± 40.3 hours in the first 10 days of life, to 73.2 ± 24.2 hours in the 11th 
to 30th postnatal day, to 41.2 ± 13.9 hours in the 31st to 70th postnatal day (40). The half-life 
during childhood remains fairly stable at 37 hours. In adults, the half-life increases to 73-139 
hours (31,41). 
Clearance 
The clearance of phenobarbitone is lower in adults - 2.1 – 4.9 ml/kg/hr, when compared to 
children - 5.3 – 14.1 ml/kg/hr (30,31,42). 
  
Drug interactions 
A drug interaction occurs when two or more drugs are administered simultaneously. A 
combination of multiple antiepileptic drugs are often used in patients not controlled with 
monotherapy. In such patients, there is often a high chance of clinically relevant drug 
interactions which can change the therapeutic outcome.  
Phenobarbitone is a potent inducer of the hepatic microsomal enzymes – CYP2C, CYP3A 
and the uridine diphosphate-glucuronosyltransferase (UGT) enzymes (20). The metabolism 
of drugs which are broken down by these enzymes can be increased, when co-administered 
with phenobarbitone. This can decrease the plasma levels of these concomitantly 
administered drugs, sometimes leading to sub therapeutic levels and loss of clinical efficacy 
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(43). On the other hand, drugs which inhibit the metabolism of phenobarbitone can increase 
the levels of phenobarbitone in plasma, leading to toxicity.  
Following are a few clinically relevant drug interactions between phenobarbitone and other 
co-administered drugs: 
 When phenobarbitone is coadministered with valproate, the metabolism of valproate 
is increased, decreasing the valproate concentration to 76% of the original 
concentration (44). On the other hand, the metabolism of phenobarbitone (both 
oxidation and glucosidation) is inhibited by valproate, increasing the plasma 
concentration of phenobarbitone by 30-50% in most patients (38,45,46). This can lead 
to sedation and drowsiness, requiring the dose of phenobarbitone to be reduced in 
upto 80% of the patients (38,47). 
 The interaction between phenobarbitone and phenytoin is quite complex giving rise to 
unpredictable changes in their plasma concentrations. Both of them are metabolised 
by the same set of enzymes and hence they can inhibit each other’s metabolism. 
When phenobarbitone is given in low doses, it increases the metabolism of phenytoin. 
On the other hand, in higher doses it inhibits the metabolism of phenytoin, increasing 
the phenytoin concentration (43).  
 Felbamate inhibits the metabolism of phenobarbitone and increases its plasma 
concentration (35). 
 Antacids reduce the absorption of phenobarbitone and decreases its plasma 
concentration (43). 
 Dextropropxyphene, stiripentol and chloramphenicol increases the plasma 
concentration of phenobarbitone by inhibiting its metabolism (45). 
 Phenobarbitone induces the metabolism of lamotrigine, topiramate, tiagabine and 
oxcarbazepine and decreases their plasma concentrations (43). Oxcarbazepine, being 
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a weak inhibitor of CYP2C19, can increase the plasma concentration of 
phenobarbitone (45). 
 Phenobarbitone increases the metabolism of carbamazepine, reducing the plasma 
concentration of carbamazepine and thereby the clinical efficacy (48,49). 
 Phenobarbitone increases the metabolism of oral contraceptives, anti-coagulants like 
warfarin and dicoumarol, corticosteroids, theophylline, antiviral drugs, cyclosporine 
and anticancer agents. Thus, the concentrations of these drugs decrease leading to loss 
of clinical efficacy (20,43). 
 
CYP450 polymorphism  
Genetic polymorphisms exist in the cytochrome P450 enzymes (50). Such polymorphisms of 
the CYP enzymes affect the expression of these enzymes, and thereby determine the 
predisposition of an individual to drug toxicity (50).  
5% of Caucasians and 20% of Asians were found to be poor CYP2C19 metabolizers (51). A 
study conducted in Japanese patients with epilepsy showed that polymorphisms of CYP2C19 
decreased the clearance of phenobarbitone (52). Another study showed that there was no 
difference in the metabolism of phenobarbitone between poor metabolizers and extensive 
metabolizers (53). 
On the other hand, ~ 35% of the Caucasians and less than 10% of the Asians and the African-
Americans had genetic polymorphisms of CYP2C9 (54). Even though phenobarbitone is 
mainly metabolized by CYP2C9 enzymes, it has not yet been reported whether CYP2C9 
polymorphisms interfere with its metabolism (27). 
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Therapeutic drug monitoring (TDM) 
Therapeutic drug monitoring is a tool for optimising drug therapy based on the relationship 
between the concentration of the drug in body fluids (usually serum or plasma) and the 
efficacy and/or toxicity (55,56). Thus it helps to optimise therapy by individualising the dose 
of the drug. Numerous biological fluids can be used for TDM such as serum, plasma, saliva, 
CSF, urine, tears or whole blood (57). 
Therapeutic drug monitoring of antiepileptic’s dates back to the late 1960’s, when the serum 
or plasma concentrations of the older antiepileptic’s – phenytoin and phenobarbitone were 
measured (57).  Nowadays, the spectrum of antiepileptic drugs being monitored with TDM is 
wide and includes drugs like carbamazepine, valproate, ethosuximide and lamotrigine (57). 
TDM of antiepileptic drugs is typically done using serum or plasma (57). The concentrations 
are usually measured at trough steady state (57).  
Criteria for a drug to be suitable for therapeutic drug monitoring (56,58) 
TDM will be particularly valuable in a drug which has the following properties: 
 Large inter-individual variation in pharmacokinetics (the pharmacokinetic variability 
can be due to genetic polymorphisms, age, gender and disease states or because of the 
variation in absorption, protein binding, metabolism, distribution and clearance). 
 Narrow therapeutic range. 
 The concentration of the drug in serum/ plasma should correlate well with the efficacy 
and/or toxicity of the drug. 
 Poor correlation between the dosage of the drug and the serum/plasma concentration. 
 The concentration of the unbound drug in serum/ plasma should correlate well or 
should be equal to the concentration of the drug in the brain (for antiepileptic drugs). 
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 Intra-individual variability in pharmacokinetics caused due to drug interactions. 
When is therapeutic drug monitoring useful? (25,26,56) 
 In suspected toxicity. 
 In suspected sub therapeutic concentrations (patients who come with failure of 
therapy). 
 To aid in dose adjustments in situations where there is increased pharmacokinetic 
variability (disease, children, elderly, pregnancy). 
 To determine patient compliance. 
 When a drug formulation is changed. 
 To determine the effect of co-medications on drug concentration. 
 To establish the concentration at which there is a good therapeutic effect. This 
concentration can be used at a later stage to determine the possible causes for a 
change in the effect of the drug. 
 Following a dose adjustment especially in drugs which exhibit non-linear 
pharmacokinetics. 
Why is therapeutic drug monitoring required for phenobarbitone? 
For a patient with epilepsy, adequate control of seizures as well of prevention of toxicity due 
to antiepileptics is essential to ensure a good quality of life. 
It is well accepted that phenobarbitone requires therapeutic drug monitoring (26,58). This is 
because the serum concentrations exhibit considerable inter-patient variability under the 
influence of age and drug interactions (26,43,45). 
At present, therapeutic drug monitoring of phenobarbitone is achieved by measuring the 
serum or plasma concentrations (26,57). The accepted therapeutic range for phenobarbitone 
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in serum/plasma is 15 - 40 mg/l (57,59). Its long half-life gives it the advantage of minimum 
variability in its concentration during a dosing interval, provided steady state has been 
attained (26). Thus blood samples for TDM of phenobarbitone can be collected at any time 
point during the day (26). 
Criteria for assays in TDM 
The assay should be: 
 Sensitive and specific with good precision and accuracy 
 Reliable and quick 
 Cost-effective 
Analytical methods 
Due to the development of numerous analytical techniques, the monitoring of drugs in 
biological matrices has been made easier. The TDM of phenobarbitone began with the use of 
UV spectrophotometry (57). However, the technique had the disadvantages of being 
cumbersome with low sensitivity and specificity (57). This was replaced by chromatographic 
techniques and immunoassay methods (60). 
The main analytical method currently used for estimation of phenobarbitone concentration in 
serum is immunoassays (26). The different immunoassay methods include enzyme-multiplied 
immunoassay technique (EMIA), fluorescence polarisation immunoassay (FPIA), cloned 
enzyme donor immunoassay (CEDIA), chemiluminescent microparticle immunoassay 
(CMIA) and particle enhanced turbidimetric inhibition immunoassay (PETINIA) (61).  
Immunoassays are widely used because of the ease of use and speed (61). They have the 
advantage of requiring low technical ability as there is no need for manual extraction of the 
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drug prior to analysis (61). They are highly sensitive, but have the disadvantage of cross-
reactivity of the antibodies used in the assay with the metabolites of the drug (57). 
The two types of chromatographic techniques are gas  liquid and high performance liquid 
chromatography (60). Even though gas liquid chromatography (GC) has enhanced sensitivity 
and specificity (57), it has the disadvantages of being highly complex in nature and being 
unable to adapt to a change according to the needs or the environment (60). Hence GC has 
largely been replaced by HPLC (62).  
Currently, HPLC is the most widely used chromatographic technique for therapeutic drug 
monitoring (62). HPLC techniques have the following advantages (57,60): 
 Sensitive  
 Specific  
 Ability to quantify multiple drugs in one separation 
 Sometimes, the known metabolites of the drugs can also be quantified 
 It is the most appropriate method to study the pharmacokinetics of a drug in order to 
evaluate the need for therapeutic drug monitoring 
HPLC requires high degree of technical precision. The cost of analysis can be overcome if a 
large number of samples are analysed at the same time.  
High  performance  liquid chromatography (HPLC) (63–67) 
Sir Mikhail S. Tswett, a Russian botanist coined the term “Chromatography” in the year 
1903. Chromatography is a technique used in analytical chemistry to separate the components 
of a mixture.  Tswett found that when a plant extract carried with the help of petroleum ether, 
is made to flow under the influence of gravity through a vertical glass tube filled with 
calcium carbonate, multiple plant pigments are separated. These were observed as coloured 
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bands along the column. The term “Chromatography” was coined from the two Greek words 
“chroma”, which means “colour” and “graphos”, which means “to draw”.  
The traditional (low pressure) liquid chromatography made use of pumps which generated 
pressures of upto 500 psi.   
High pressure liquid chromatography, currently known as High performance liquid 
chromatography, is a form of liquid chromatography used to separate the components of a 
liquid mixture so as to purify, identify and quantify the individual components. It is different 
from the traditional liquid chromatography in the fact that it makes use of smaller columns 
and higher pump pressures which gives it high resolution separation and speed when 
separating the components of a mixture. 
The term “High pressure liquid chromatography” was coined by the late Sir Csaba Horváth, a 
Hungarian chemical engineer in 1970. In the 1980’s, the name was changed to “High 
performance liquid chromatography”. 
The HPLC Instrument 
A HPLC instrument is typically composed of two to four pumps, an injector, a column, a 
detector and a data processing unit and display. The system may or may not have a column 
heater and the area for specimens prior to injection may or may not have temperature control. 
The sample containing the analytes is introduced through the injector port into an isolated 
sample loop. The valves within the rheodyne system move to open the channels which bring 
the mobile phase into the loop. The mobile phase flows into the loop, picks up the sample and 
takes it to the column. As the sample moves through the column, different analytes move at 
different velocities which lead to the separation of the analytes. The velocity with which a 
particular analyte moves depends on the interaction of the analyte with the stationary and 
mobile phases. If the analyte has greater affinity for the mobile phase when compared to the 
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stationary phase, then it will move with greater velocity and will elute from the column 
earlier than analytes which have an affinity for the stationary phase.  
The interaction/ affinity is based on the principle of “Like attracts Like” or polarity. If the 
stationary phase is polar and the mobile phase non polar, then non polar compounds will elute 
first, followed by the polar compounds. 
The time taken for a specific analyte to emerge from the column following its injection under 
a particular set of conditions is fixed and is called the retention time (RT).  
From the column the analytes move to the detector whose signal is represented as a 
chromatographic peak.  
Figure 3: Automated Injector Shimadzu LC 2010 CHT- diagram of internal section 
 
Source: Schimadzu LC 2010HT (High pressure liquid chromatograph) 
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Pump  
The pump generates the pressure that is required to transport the mobile phase carrying the 
sample through the column. Current pumps can generate pressures upto 6000 psi. The pump 
controls the flow rate (Normal flow rate = 1-2 ml/minute for a column with an internal 
diameter of 4.6 mm). The pump also delivers the desired composition of mobile phase to the 
column. The instrument can be programmed for two different types of elution as given below. 
 Isocratic elution:  
In isocratic elution, the composition of the mobile phase is kept constant throughout the 
analysis. An isocratic elution is used to separate the components of a mixture which are quite 
similar to each other in their affinity for the stationary phase. 
e.g.: 70% Water + 30% Acetonitrile throughout the time of analysis  
 Gradient elution: 
In gradient elution, the composition of the mobile phase is changed with time during the 
analysis. Typically in gradient elution, the composition of the mobile phase is changed from 
low eluting strength to high eluting strength. The high eluting strength will enable the late 
eluting compounds to elute out faster and have a shorter retention time. 
e.g.: A gradient starting at 10% Acetonitrile in water and ending with 70% Acetonitrile in 
water towards the end of analysis 
 
In isocratic elution, the peak becomes broader as the retention time increases. Thus, in this 
scenario the late eluting compounds will have very broad peaks, which will make it difficult 
to identify them as definite peaks. Gradient elution will decrease the retention time of the late 
eluting compounds and enable the peak shape to be better defined. 
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Injector 
The injector will serve to introduce the sample into the moving mobile phase. Injection of the 
sample can be manual or automated. 
An “Autosampler” or an automated injector becomes useful when there are numerous 
specimens to be analysed and hence the use of a manual injector becomes difficult and 
cumbersome. The extracted specimens are loaded onto an autosampler tray (capacity of 100 
specimens). The appropriate volume of specimen is drawn into the autosampler needle, which 
is then transported by the mobile phase to the column. The needle is flushed prior to injecting 
the next sample. 
 
Detector 
Ultra-violet detector (UV detector): 
It is one of the most commonly used detectors in HPLC. It is an absorbance detector.  
Principle of UV detector: 
At the time of analysis, the sample moves through the flow cell. A light source will emit 
ultraviolet light, which is irradiated through the flow cell. This ultra-violet beam falls on a 
sensor which is located at the other end. The sensor measures the amount of light falling on 
it. If an analyte eluting from the column absorbs this UV light as it flows through the flow 
cell, the amount of light falling on the sensor changes. The amount of light absorbed by an 
analyte is proportional to the concentration of the analyte. 
There are two types of ultra-violet detectors – fixed wavelength and variable wavelength.  
In the fixed wavelength type, a lamp is used (usually mercury vapour lamp), which emits a 
single wavelength.  Because the intensity of the wavelength emitted is high, fixed wavelength 
detectors are several times more sensitive than variable wavelength detectors. 
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In variable wavelength detectors, a deuterium lamp is usually used, which emits a broad 
range of wavelength. The wavelengths are irradiated onto a diffraction grating, which 
functions just like a prism and separates the wavelengths. The light is now made to pass 
through a barrier with a tiny slit. Adjustments are made such that only a selected wavelength 
is allowed to pass through the slit. The selected wavelength passes through the sample and 
the sample absorbs part of the light.  
Data processing Unit and Display 
The detector provides an output, which is picked up by the data processing unit and displayed 
on the computer screen as a “Chromatogram”. Each peak on the chromatogram denotes a 
separated analyte which has emerged from the column.  
The Mobile and Stationary Phases in HPLC 
Mobile phase 
It is a liquid phase which helps to carry the specimen through the column. In reversed phase 
chromatography (RPLC), the mobile phase is usually a combination of water with an organic 
solvent like methanol or acetonitrile (polar solvents). The choice of mobile phase for an assay 
depends on the interaction of the mobile phase with the stationary phase and the analyte. The 
pH of the mobile phase can be adjusted by adding a buffer. In RPLC, the pH is usually 
between 2 - 8.  
Buffers are important in RPLC for mainly two reasons: 
1. For analytes prone to ionization, the buffer ensures that the analyte exists in a single 
form – ionized or unionized. This ensures a good peak shape. 
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2. If the pH range of the analyte is such that it can damage the column, the buffer 
changes it to a less harmful pH. 
Phosphate buffer is the most common type of buffer. The concentration of the buffer is 
usually in the range of 25 to 50 mM. 
 
Stationary phase 
The stationary phase consists of an immobile solid phase packed within a column. It could be 
made up of either polar compounds like silica or alumni which are porous in nature or non-
polar compounds like C18 and C8 which are bonded onto the surface of the porous particles. 
e.g.: bonded silica. 
Reversed - phase Chromatography 
In reversed - phase chromatography, the stationary phase is non polar (e.g.: silica bonded 
with –C18), while the mobile phase is polar (e.g.: methanol). Hence, the polar analytes will 
elute out quickly, while the non-polar analytes will be retained in the column longer, and will 
elute out later. 
Characteristics of the column 
Tubing of the column 
The outer tubing of the column can be made of stainless steel, glass or PEEK polymer. 
Stainless steel is the most commonly used material since it enables the column to withstand 
very high pressures.  
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Chemistry of the column 
The most commonly used packing material in the manufacture of stationary phase is silica, 
which is polar (hydrophilic) in nature. The silica can be made non-polar by bonding it with 
ligands like -C18, -C8, -C4 and -Cyano groups. A polar stationary phase is used in normal 
phase HPLC, while a non-polar stationary phase is used in reversed phase HPLC. 
Carbon load - It is a measure of the amount of bonded ligands which are attached to the 
surface of the packing material. With a low carbon load, the retention time is usually faster. 
End–capping – Silica is a polymer which terminates on the surface as – Si-OH groups 
(Silanols). The bonded ligands like –C 18, attach themselves to the silica through the silanols. 
However, because of the large size or bulkiness of the bonded ligands, all the exposed 
silanols are not bonded. These exposed silanols being acidic in nature, can react excessively 
with basic analytes and produce tailing of peaks. Hence, these unbound silanols (also called 
as “residual” silanols) are made less reactive by bonding it with smaller ligands. This is called 
as “End – capping”.   
 
Particle Size 
The stationary phase is usually made up of smaller particles. As the particle size decreases, 
the surface area available for interaction increases, which enables better separation of the 
components of a mixture.  
However, as the particle size decreases, the back pressure of the column increases. This 
necessitates the use of pumps which can generate higher pressures. The particle size in HPLC 
columns ranges between 2 – 25 µm. The most commonly used particle size is 5 µm. 
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Particle shape 
The stationary phase can be made up of either uniform spherical particles or irregular 
particles. Spherical particles have the advantage of easy manufacturing, higher efficiency, 
better stability of the column and lower back pressures. The columns composed of irregularly 
shaped particles are usually more difficult to manufacture. 
 
Pore size 
The stationary phase is usually porous to increase the surface area available for interaction. 
The pore size of the particles denotes the average size of the pores which are present within 
each particle. As the pore size increases, the surface area available for interaction decreases. 
The molecular weight (size) of the analyte should be taken into consideration prior to 
choosing the pore size as given below: 
Molecular weight < 3000 - Pore size of < 100 A°  
Molecular weight of 3000 - 10,000 - Pore size of 100 – 130 A°  
Molecular weight > 10,000 - Pore size of 300 A°  
 
Column length 
Longer columns provide better separation (with the same pore size). However, the run time, 
mobile phase consumption and back pressure increases with the length of the column. 
Usually, the HPLC columns are between 50 – 300 mm long. 
 
Internal diameter of the column 
Narrower columns have the advantage of better sensitivity of detection and lesser mobile 
phase consumption. However, only small quantities of the sample can be loaded onto the 
column when compared to wider columns which have a large loading capacity. Also, as the 
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internal diameter increases, the back pressure decreases. Hence, wider columns have the 
advantage of lower back pressure. Since wider columns generate lower back pressures, it 
enables them to have a higher flow rate. Therefore, as the internal diameter increases, the 
flow rate increases.  
                         Flow rate                      Column diameter 
                     1 - 2 ml/minute                              4.6 mm 
                     0.4 – 0.6 ml/minute                              3.0 mm 
                     0.2 – 0.4 ml/minute                              2.1 mm 
 
Column Temperature 
The control of column temperature becomes important in the following situations: 
 High temperatures can lead to breakoff of the bonded phase from the packing material 
as well as dissolution of silica. Hence, the maximum temperature to which the 
stationary phase can be exposed should be crosschecked prior to use. 
 Certain chemical compounds like enzymes and proteins may be unstable at room 
temperature and hence will need lower temperatures during analysis.  
 The retention time for certain compounds is temperature dependent. Variation in the 
temperature can lead to variation in the area/ height of the peaks.  
The temperature of the column can be controlled using an oven or a water bath. 
 
Column Pressure 
The column pressure is directly proportional to the viscosity of mobile phase, length of 
column and the flow rate. The flow rate should always be set such that it does not over-
pressurise the pump. Also, a mobile phase with the lowest viscosity should be chosen. 
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Guard Column 
The guard column is placed between the injector and the column. It filters any particulate 
contaminants which may be present in the sample or the mobile phase and retain it. Thus, it 
protects the column from contaminants which can destroy / block the column and increases 
the longevity of the column. 
Also, the column has an inlet frit. Frits are present on either ends of the column and prevent 
the exposure of the packing material. In the absence of a guard column, particulate 
contaminants can get collected at the column inlet frit and plug the column. This can lead to 
tailing and splitting of the peaks, thereby affecting the analysis.  
 
Retention time (RT) 
Under a particular standardised set of conditions, the retention time is characteristic of an 
analyte and can be used to identify the analyte. 
The retention time can vary with: 
 Flow rate 
 Composition of mobile phase 
 Nature of the stationary phase 
 Temperature of the column 
Quantifying the analyte 
The amount of analyte is quantified by measuring the area under the peak. The area under the 
peak is proportional to the amount of analyte. The steps in quantifying the analyte have been 
described in the section “Calculation of the unknown concentration of Phenobarbitone” on 
pages 62 & 63. 
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Figure 4:  Example of ‘Chromatogram’ 
 
                                      
 
 
  
Compound A 
Compound B 
      Chromatographic peaks, each       
              denoting one analyte 
Retention time of Compound A - 8.67 minutes 
 Retention time of Compound B - 14.45 minutes 
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Dried blood spot (DBS) 
Dried blood spot refers to the analysis of whole blood spotted and dried on a filter paper (68). 
This technique was first described over a century ago by Ivar Christian Bang, when he used 
dried blood spots for measurement of blood glucose in rabbits (68). Its first clinical 
application came in the early 1960’s, when Dr Robert Guthrie used DBS for detection of the 
metabolic disorder, phenylketonuria in newborns (68).  
 
Applications of Dried blood spot 
Currently, the most common application of DBS specimens is to screen neonates for genetic 
and metabolic disorders like cystic fibrosis, phenylketonuria, congenital adrenal hyperplasia 
and hypothyroidism (68). It is also used in large scale epidemiological studies to screen for 
various biological markers like enzymes, hormones, vitamins and specific antigens and 
antibodies (69). Its application in the field of therapeutic drug monitoring is a more recent 
development and hence not so common (69). It is also used to perform pharmacokinetic 
studies in children to develop a dosing regimen for drugs (70). This is a very important use of 
DBS analysis, since often the dosing regimen of many drugs in children is obtained from the 
pharmacokinetic data of adults which could lead to prescribing sub therapeutic or toxic doses 
(70).  Also, pharmacokinetic studies in children often require repeated blood sampling with 
relatively large blood volumes being taken at time of each sampling (70). This is overcome 
by the use of DBS for analysis. In the field of clinical chemistry, numerous analytes like 
nucleic acids, peptides, proteins and lipids are measured using the DBS technique (68,69). 
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A few uses of the dried blood spot other than neonatal screening include measuring 
ceruloplasmin levels in Wilson’s disease, HbA1C in diabetes mellitus, CD4 counts in HIV and 
thyroxin binding globulin during screening for neonatal hypothyroidism (68). 
TDM of antiepileptic drugs using DBS  
A number of general articles have been published on antiepileptic drug measurements from 
dried blood spot.  
Wegner at el have shown the use of dried blood spot for measuring both lamotrigine and 
oxcarbazepine concentrations in pregnancy (71). Filippi et al measured the plasma 
concentration of topiramate in neonates by correcting the values obtained on a dried blood 
spot (72). The topiramate concentration in DBS was measured using liquid chromatography 
tandem mass spectrometry (LC-MS/MS) (72). 
 There were very few papers giving hard data on the correlation between the concentrations 
of antiepileptic’s in plasma/serum and dried blood spot. Most of the papers giving this type of 
data are related to the newer, and not the older antiepileptic’s. Soons et al found that there 
was a good correlation between the concentration of lamotrigine measured in plasma and 
DBS (73). The dried blood spot analysis was done using reversed phase HPLC (73). A study 
done by Marca et al in Italy found that there was no significant difference between the 
concentrations of phenobarbitone measured in plasma and DBS specimens (74). The above 
study measured the plasma concentration using immunoassay and the dried blood spot 
concentration using LC-MS/MS (74). Our study aimed at going a step further in predicting 
the phenobarbitone concentration in serum from that in DBS by formulating an equation. 
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Collection and Sampling 
Sampling can be done using two methods: 
1. Finger prick method (68,69,75) 
This method involves the use of a sterile lancet to puncture the skin at the heel, toe or 
finger. Once the first drop of blood is discarded, subsequent drops are blotted on the 
premarked circles of the DBS card (filter paper). Squeezing the puncture should be 
avoided as it causes haemolysis and dilution of the blood with tissue fluids. The circle 
should be completely and homogenously filled with blood. A typical DBS card 
(Whatman Protein Saver #903) is made up of 5 half - inch circles, each with a 
capacity to hold 75 - 80 µl of blood. Only one drop of blood should be applied per 
circle, without touching the circle. Supersaturating, clotting or layering of the blood 
should be avoided. If the blood obtained with the finger prick is contaminated, 
haemolysed or inadequate, it cannot be used for blotting on the filter paper. 
2. Using a micropipette (69,75)  
In this method, a known volume of blood is accurately pipetted with a calibrated 
micropipette onto the filter paper. The tip of the pipette should not touch the filter 
paper and the blood should be quickly expelled as soon as the drop of blood comes in 
contact with the filter paper.  
Drawbacks of the finger prick method  
The collection of blood from a finger prick has a number of problems. A few examples are 
given below, all of which can lead to wastage as the specimens will have to be discarded. 
(76).  
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Figure 5: Drawbacks of the finger prick method 
1. Inadequate volume of  blood 
     
2. Finger touching or scratching the surface 
 
3. Clotting or layered specimens – this occurs if the blood drop is touched to the paper 
several times 
 
It has been proposed that patients given clear instructions and adequate training in finger 
prick sampling may be able to send the DBS to the laboratory for monitoring (68). However, 
as Stock et al pointed out in a presentation to the International Association of Therapeutic 
Drug Monitoring and Clinical Toxicology, there are a number a drawbacks to this (77). 
1. Sampling is not under the control of the hospital. 
2. Despite training, the quality of some samples is not satisfactory and can lead to 
problems as shown in the figure above (Figure 5) (69). 
3. Some patients have a fear of finger prick (69). 
Photos reproduced from: ACTN Laboratory Technologist Committee Version 1.1, ACTN Dried blood 
spots : Procedure 11 March 2009. Dried blood spots card collection, processing and storage procedures 
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4. The small sample volume limits the number of repeat specimens. 
5. The small sample volume also means that usually only one analyte can be measured 
per specimen. 
For these reasons, we will use the second of the methods described above (using a 
micropipette) for spotting blood in our study. 
Filter paper 
A Protein Saver #903 card/paper is available from Whatman for DBS analysis (75). It is an 
FDA listed class 2 medical device used extensively for neonatal screening (75). However, 
these cards are expensive and not freely available in India. An alternative is to use the 
standard Whatmann filter paper.  
Drying of the DBS specimen 
After spotting, the DBS papers are completely air dried at room temperature on a non-
absorbent surface (68). The duration for which the papers are dried depends on the type of 
paper and the volume of spotted blood (69). The DBS cards used for neonatal screening are 
air dried for a minimum of 3 hours at a temperature of 15 – 22 °C (69). During drying, the 
specimens should not be piled on top of each other or allowed to come in contact with any 
other surface (75). Exposure to direct sunlight should also be avoided (75). 
 It is important to completely dry the papers prior to storage, as any left-over moisture can 
promote bacterial growth, interfere with the elution time of the analyte or cause breakdown of 
unstable analytes (75,78). Drying the blood spot reduces the risk of infection by destroying 
the capsid of the following viruses (Hepatitis C virus, Human T-lymphotropic virus, Human 
immunodeficiency virus, Cytomegalovirus) (68).  
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Storage of the DBS specimen 
After drying, the DBS specimens should be stored in zip lock bags with low gas permeability 
along with a desiccant to prevent the accumulation of moisture (75). During storage, either an 
individual zip lock bag should be used or the specimens should be separated from each other 
using a thick paper to reduce the risk of cross-contamination (68). A humidity indicator 
should also be placed in the storage package (75). Thus if properly stored, the DBS 
specimens will remain stable at room temperature for several weeks, months or years 
depending on the analyte (75). 
Transport of the DBS specimen 
Once the DBS specimens are completely dried, they can be transported by regular mail 
without any biohazard risk (69,75) . They should be packed in the zip lock bags as mentioned 
above with a paper overlaying the specimen, and sent by mail in a good quality bond 
envelope (75).  
Methods for measuring the analyte  
There are two methods for measuring the DBS (69).  
The first method is called the “Disc punch method”. This makes use of a specially designed 
punching device to cut out a 2-8 mm (diameter) disc from the filter paper (68,69). This disc is 
subjected to analysis. The disc depending on the diameter, will contain a specific volume of 
blood similar to that of a liquid measurement (69). This method must be used if the specimen 
is collected from a finger prick. 
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Figure 6: Disc punch method                     
       
                                    
The second method is to cut out the whole DBS from the filter paper and use it for the 
extraction as shown in figure 7 (69). The second method can be used for specimens created 
from dropping a known volume of whole blood onto the filter paper (69). Since the volume is 
known, there is no need to apply any correction factor for the differing weights in the filter 
paper (69). This method must be used for specimens spotted using a micropipette.  
 
Figure 7: Cutting out the whole blood spot (second method) 
                         
Stability of DBS 
DBS specimens if stored properly, are stable at room temperature for several weeks to years 
depending on the analyte (75). 
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Studies show that the minimum stability period for majority of the analytes in a DBS is 7 
days at room temperature (68). DBS has been found to increase the stability of certain 
compounds like opioids (68). Nucleic acids can be stored in a DBS for several months at 
room temperature, and for several years at – 20 °C (68). Glycated haemoglobin can be 
analysed from DBS upto 15 days after spotting (68). Lipids, sugars and small organic and 
inorganic molecules like vitamin D and triglycerides remain stable for a duration of 30 days 
at room temperature (68). At a lower temperature of 4 °C, they can be stored for upto 90 days 
(68). An FDA validated DBS method which can quantify nine anti-retroviral drugs showed 
the stability of these drugs for 12 to 90 days at room temperature (68).  
Numerous assays developed for quantifying drugs from DBS report the stability of these 
drugs in the dried blood (69). Amodiaquine, the antimalarial drug was found to be stable for 
upto 30 days at 4 °C and 1 day at room temperature (69) . While cyclosporine was found to 
be stable upto 4 weeks at room temperature, dapsone was stable for 3 months when stored 
between – 20 °C to + 35 °C  (69). 
Advantages of DBS for analysis (68,69,75,79) 
The advantages of DBS include: 
i. A smaller volume of blood is required for DBS analysis when compared to using 
the conventional serum/plasma. 
ii. It is a relatively non-invasive method if the finger or heel prick is used for blood 
collection. 
iii. It reduces the risk of infection (biohazard risk) during handling to a minimum. 
iv. Being stable at room temperature it does not require freezers or dry ice for 
storage, unlike serum and plasma. 
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v. Because of the stability and the low risk of infection, DBS specimens can be 
easily transported in a cheap manner without the need for cold chain.  They can be 
transported by ordinary mail to the laboratory for analysis.  
vi. The whole blood sample collected for DBS does not need to be centrifuged, 
separated or frozen immediately (unlike the sample collected for serum/plasma 
analysis). 
vii. If adequately trained, patients can themselves carry out the sampling at home. 
Disadvantages of dried blood spot for analysis (68,69) 
The disadvantages of DBS include: 
i) Since very small blood volumes are used for analysis, the sensitivity of the assay 
should be high. 
ii) The small sample volume limits the number of repeat specimens. 
iii) Despite adequate training, the sampling when done by the patient often does not 
meet the required standard leading to wastage of specimens. 
iv) If very low concentrations of analytes need to be measured, extremely sensitive 
analytical techniques like mass spectrometry will be required. This increases the 
cost of analysis 
v) The haemoglobin and other intracellular matter released from haemolysed RBC’s 
can produce interferences in the assay. 
vi)  The proteins in the blood can get denatured during drying thereby changing the 
enzymatic activity of the proteins. 
vii) The analysis of DBS specimens gives the concentration of the analyte in whole 
blood. However, the therapeutic range for most drugs has been reported in 
serum/plasma. Hence a therapeutic range of the drug in whole blood should be 
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defined or conversion of the whole blood values to serum/plasma values should be 
done by means of an equation. 
viii) Haematocrit has been found to influence the dispersion of the blood in the filter 
paper. Hence, haematocrit needs to be taken into account when calculating the 
concentration. 
Summary and justification for the study 
Phenobarbitone is a commonly used antiepileptic for the treatment of partial and various 
types of generalised seizures. It is well accepted that phenobarbitone requires therapeutic 
drug monitoring due to its variable pharmacokinetics and numerous clinically relevant drug 
interactions.  
Phenobarbitone is usually measured using serum or plasma levels. An alternative method to 
measure drug concentrations, which is gaining popularity in the therapeutic circles, is the use 
of DBS. The advantage of dried blood spot over serum is that these samples are stable, easy 
to store and transport. They are less of a biohazard risk to handlers when compared to whole 
blood, plasma or serum.  
The aim of this study is to determine if an equation needs to be developed that will accurately 
predict the concentration of phenobarbitone in serum from that measure in dried blood spot. 
The reason for this is that the therapeutic range is for serum and not for dried blood spot.  
Patients who are on phenobarbitone and who fulfil the inclusion criteria will be enrolled into 
the study after obtaining informed consent. Blood is collected by venepuncture for analysis. 
Whole blood (20 µl) will spotted on the standard Whatman filter paper, which is then air 
dried and the concentration measured by High Performance Liquid Chromatography. 
Simultaneously, the concentration of phenobarbitone in serum is measured by HPLC. If the 
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concentration of phenobarbitone can be accurately predicted from a dried blood spot 
specimen, then this can be used by smaller or rural hospitals to send samples for 
phenobarbitone monitoring to a higher center, in a safer and cheaper manner.  
The correlation will be determined between the phenobarbitone concentration in the DBS 
specimen and that in serum for all the patients. The patients will be divided into two groups 
of approximately 50% by random allocation. The first group will be used to generate a 
regression equation and the second group will be act a validation group. Validation will be 
performed by bootstrap method. 
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Methodology 
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Chemicals and reagents 
Phenobarbital pure powder was obtained from the pharmacy of Christian Medical College 
and Hospital, Vellore. The internal standard used for the dried blood spot assay – 4 -
aminoacetophenone was purchased from Sigma Aldrich, India. The internal standard used for 
the serum assay – Ornidazole, was also obtained from the pharmacy of Christian Medical 
College and Hospital, Vellore.  
Acetonitrile (ACN) and methanol used for the assay were of HPLC grade and supplied by 
Thermo Fisher Scientific Private Limited, Mumbai, India. The phosphate salts used in the 
preparation of the buffer – di-potassium hydrogen phosphate (K2HPO4) and potassium 
dihydrogen orthophosphate (KH2PO4) were also of HPLC grade and obtained from Thermo 
Fisher Scientific Private Limited, Mumbai, India. 
Deionised water purified using the Millipore Milli-Q apparatus (Merit Enterprises, Chennai, 
India) was used for the assay. 
Equipment 
 Automated Injector High Performance Liquid Chromatography LC – 2010CHT 
instrument with UV detection [Shimadzu Analytical (India) Pvt. Ltd.].  
 HPLC Column - 4.6 mm * 250 mm C -18 column (5 µm particle size, 300 A° pore 
size), purchased from Thermo Fischer Scientific India Private Limited, Mumbai, 
India. 
 HNN membrane disc filter with a pore size of 0.22 micrometre (Nupore Filtration 
Systems Private Limited, Ghaziabad, India) - required for the filtration of the prepared 
buffer and the organic solvents - Acetonitrile and Methanol.  The HNN membrane 
disc filters are biologically inert and hydrophilic in nature. 
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 Filtration apparatus – comprising of a membrane filter holder (membrane diameter – 
47 mm) and a conical flask (volume – 1000ml) from Science house, Chennai, India. 
 Qualitative Grade 1 Whatman filter paper, diameter 125mm (GE Healthcare UK 
Limited, United Kingdom) - used for spotting whole blood. 
 Single tube vortex (Model – CM 101, Science House, Chennai, India). 
 Centrifuge – Rota 4R-V/Fm (Science House, Chennai, India).  
 Micropipettes (Model – Erba Biohit (1-CH), Transasia Bio-medicals Ltd., Mumbai, 
India) - Adjustable for volumes 20 µl - 1000 µl. 
 Micropipette tips (Tarsons Products Pvt. Ltd., Kolkata, India). 
 Disposable 1.5 ml eppendorf tubes (Tarsons Products Pvt. Ltd., Kolkata, India) for 
extraction.  
 Disposable 350 µl plastic vials (Crescent Scientific Private Limited, Chennai, India). 
 Ultra-sonicator (Model – 9L-250, Associated Instruments and Chemicals, Chennai, 
India) for degassing mobile phases. 
HPLC conditions and validation of the assays 
A. Serum 
HPLC conditions for extraction of phenobarbitone from serum 
Instrument – Automated Injector Shimadzu LC 2010 CHT 
Column – Discovery C18 (5 µm, 300 A°, 250 mm * 4.6 mm) 
Buffer – 29 mM phosphate buffer (pH – 6.9) 
Mobile phase – 20% acetonitrile + 80% buffer 
Isocratic elution 
Flow rate – 1.3 ml/minute 
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Wavelength – 214 nm, 254 nm (UV detector) 
Loop – 20 µl 
Temperature – Ambient 
 
Preparation of drug stock solution (for standards and QC preparation) 
A stock solution of phenobarbitone - 1 µg/µl, was prepared by dissolving 100 mg of pure 
phenobarbitone powder in 20 ml of Isopropanol and make up the volume to 100 ml with 
water. Separate stock solutions of 1 µg/µl each were made for preparation of standards and 
quality control (QC). 
 
Preparation of serum standards and quality control 
From 1 µg/µl standard stock(1), the following working standards were prepared:                                  
50, 30, 20, 10, 5 & 2.5 µg/ml                                                                                                           
Std 50 µg/ml = 200 µl of Std stock 1 µg/µl + 3800 µl of calf serum 
Std 30 µg/ml = 120 µl of Std stock 1 µg/µl + 3880 µl of calf serum 
Std 20 µg/ml = 80 µl of Std stock 1 µg/µl + 3920 µl of calf serum 
Std 10 µg/ml = 40 µl of Std stock 1 µg/µl + 3960 µl of calf serum 
Std 5 µg/ml = 20 µl of Std stock 1 µg/µl + 3980 µl of calf serum 
Std 2.5 µg/ml = 1000 µl of 5 µg/ml + 1000 µl of calf serum    
       
A separate stock was made for the Quality Control specimens. 
From 1 µg/µl QC stock, working QC – 15 µg/ml was prepared: 
Qc 15 µg/ml = 60 µl of QC stock 1 µg/µl + 3940 µl of calf serum  
From 1 µg/µl QC stock, the following concentrations were prepared to be used in the 
validation process as low, medium and high QC: 
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Low QC (7 µg/ml) = 35 µl of Std stock 1 µg/µl + 4965 µl of calf serum 
Medium QC (20 µg/ml) = 80 µl of Std stock 1 µg/µl + 3920 µl of calf serum 
High QC (50 µg/ml) = 200 µl of Std stock 1 µg/µl + 3800 µl of calf serum 
 
Preparation of internal standard for extraction from serum 
A stock solution of internal standard (IS) – Ornidazole (1µg/µl) was prepared as follows: 
2 mg of Ornidazole pure powder dissolved in 2 ml of acetonitrile = 1 µg/µl of Ornidazole 
stock. 
 
Preparation of extraction solvent containing internal standard for extraction from 
serum 
30 µl of 1 µg/µl of Ornidazole stock + 970 µl of acetonitrile = 30 µg of Ornidazole in 1 ml of 
ACN 
 
Extraction 
The specimens were extracted by the precipitation method. There were certain considerations 
taken into account. 
1. Which solvent/solution should be used for precipitation? For example acetonitrile, 
methanol or trichloroacetic acid is commonly used.  
2. Our analyte (drug of interest) must be soluble and stable in the precipitating solvent 
chosen. 
3. What is my biological matrix and does precipitation remove interfering substances 
present in the biological matrix adequately (assessed by running blank serum 
specimens in the HPLC conditions)? 
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4. Does precipitation alone give the sensitivity required for the analyte or is 
concentration to dryness and reconstitution required? 
 
Extraction by precipitation 
Extraction by precipitation is one method used to extract drugs from biological matrices.  
Following the addition of solvent to the biological matrix containing the analyte, the mixture 
is vortexed (cyclomixed) at high speed for 1 minute.  During this time precipitation of the 
proteins occurs. The specimen is then centrifuged at 9447g for 5 minutes to reduce the 
protein precipitate and other matrix components to a hard pellet thus reduces the interfering 
compounds in the analysis.  The clear supernatant containing drug may be removed easily 
from this pellet and placed in a clean eppendorf.  To concentrate the analyte this supernatant 
is evaporated to dryness. It is then reconstituted in mobile phase or an appropriate solvent, 
and injected. 
The steps in the extraction of phenobarbitone from serum are shown in figure 8.  
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Figure 8: Serum Assay for Phenobarbitone 
 
 
Development and validation of the assay for the extraction of 
phenobarbitone from serum 
Validation of analytical methods is performed to ensure that the methodology used is reliable 
and reproducible when used to quantitatively measure the analyte in the biological matrix of 
interest. 
A) Water standards – To determine the retention time of the analyte and Internal 
standard 
Water standards of the drug and the internal standard are prepared by spiking deionised water 
(Millipore water) with the analyte (drug) and the internal standard respectively. Using these 
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standards the retention time of the drug and the internal standard under a particular set of 
HPLC conditions are determined. Water standards containing the drug – phenobarbitone and 
the internal standard – Ornidazole were prepared and analysed to detect the retention time. 
 
B) Blank matrix specimens  
Blank specimens are matrix specimens without the drug or the IS. They are analysed to 
ensure selectivity of the analyte i.e. we should be able to differentiate and quantify the 
analyte even when other components are present in the sample.  
Blank specimens of serum were obtained from 10 different sources. The blank specimens 
were obtained both from a similar cohort of patients (patients on antiepileptics other than 
phenobarbitone) as well as from patients who were not on anti-epileptics, but on other drugs. 
These blank specimens were analysed for the presence of interference under the drug and the 
IS peak in the chromatogram. The chromatogram traces from the blank specimens were 
compared against that for std 5. From this interference from the following antiepileptics was 
excluded – phenytoin, carbamazepine, valproate, oxcarbazepine, lamotrigine, levetiracetam, 
clonazepam, clobazam and topiramate. 
 
C) Non-zero specimens – expected concentration range 
Specimens from 10 different patients on phenobarbitone were analysed to determine an 
expected range in the concentrations of the study specimens.  
 
D) Calibration curve - Linearity 
Calibrators (standards) were prepared by spiking serum with known concentrations of 
phenobarbitone. Based on the analysis of non-zero specimens, the expected range of 
concentrations in the study specimens were found to be between 2.5µg/ml to 50µg/ml. 
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Six calibrators were prepared – 50, 30, 20, 10, 5 & 2.5 µg/ml from the standard stock 
solution. The QC - 15µg/ml was prepared from a separate QC stock solution. The preparation 
of the calibrators and QC is shown in the section – (Preparation of serum standards and 
quality control, page 56 & 57).   
6 different calibration runs were performed over a span of several days using freshly prepared 
standards to ensure linearity of the standard curve.  
 
E) Intra-day variability (same batch, same day) 
On the same day, the following analysis was performed: 
Standard 5: Extracted 5 times from a single aliquot and the extraction analysed.  
Standard 50:  Extracted 5 times from a single aliquot and the extraction analysed.  
The % coefficient of variation (%CV) was calculated at each concentration. This test checks 
the   intra – day variation in the assay at the high and low concentrations. 
 
F) Inter-day variability (same batch, different days) 
The inter-day variability in the assay was assessed by using low (7 µg/ml), medium (20 
µg/ml) high (50 µg/ml) concentration spiked specimens.  
The preparation of these specimens is shown in the section – (Preparation of serum standards 
and quality control, page 56 & 57).   
High Concentration: Day 1:  Three extractions performed and run by HPLC. 
                                 Day 2:  Three extractions performed and run by HPLC.  
The medium and low concentrations were treated in the same way. The % CV was calculated 
for each concentration. 
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G) Reproducibility of injection 
Reproducibility of injection was checked by using a high concentration and a low 
concentration. 
Standard 50 was extracted once and 5 repeat injections were given from the same extract. 
Standard 5 was extracted once and 5 repeat injections were given from the same extract. 
% CV was calculated for each concentration. The repeat injections from the same extract 
checked the reproducibility of the instrument. 
 
H) Sensitivity 
Sensitivity refers to the lowest concentration of analyte which can be measured within the 
acceptable limits of precision and accuracy (80). As this is an assay for drug monitoring and 
the therapeutic range is 15 – 40 µg/ml, any concentration ≤ 10µg/ml is very low and it is 
therefore not necessary to calculate a lower limit of quantification (LLOQ). The lowest 
standard quantitated in the serum was 2.5 µg/ml. 
 
I) Stability 
Phenobarbitone is known to be stable in serum/ plasma for a period of four weeks when 
stored at - 20 °C (81,82)  
 
Calculation of the unknown concentration of phenobarbitone 
The ratio of the area of the drug peak with that of the internal standard, is calculated for all 
the standards and QC. A linear regression line is plotted with the concentrations on the x – 
axis and the ratios on the y-axis. The slope, intercept and correlation coefficient is calculated 
from the regression line.  
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The unknown concentration of phenobarbitone in serum (and dried blood spot) is calculated 
using the linear regression equation y= bx + a where : 
a = calculated intercept based on your standard curve     
b = calculated slope based on your standard curve   
The unknown concentration is calculated by: [Unknown Concentration Ratio – a] / b 
 
HPLC conditions and validation of the assays 
B. Dried blood spot 
HPLC conditions for extraction of phenobarbitone from dried blood spot 
Instrument – Automated Schimadzu LC 2010 CHT 
Column – Thermo Scientific C18 (5 µm, 300 A°, 250 mm * 4.6 mm) 
Buffer – 29 mM phosphate buffer (pH – 6.9) 
Mobile phase – 19% acetonitrile + 81% buffer 
Elution: Isocratic 
Flow rate – 1.2 ml/minute 
Wavelength – 214 nm, 254 nm (UV detector) 
Loop – 20 µl 
Temperature – Ambient 
 
Preparation of Dried blood spot standards and quality control 
From the 1 µg/µl standard stock, the following working standards were prepared – 40, 30, 15, 
5 & 2.5 µg/ml. 
Std 40 µg/ml = 80 µl of Std stock 1 µg/µl + 1920 µl of whole blood 
Std 30 µg/ml = 60 µl of Std stock 1 µg/µl + 1940 µl of whole blood 
64 
 
Std 15 µg/ml = 30 µl of Std stock 1 µg/µl + 1970 µl of whole blood  
Std 5 µg/ml = 20 µl of Std stock 1 µg/µl + 3980 µl of whole blood 
Std 2.5 µg/ml = 1000 µl of Std 5 µg/ml + 1000 µl of whole blood 
 
From the 1 µg/µl quality control stock, the working QC – 10µg/ml was prepared: 
QC (10 µg/ml) = 20 µl of QC stock 1 µg/µl + 1980 µl of whole blood  
From 1 µg/µl QC stock, the following concentrations were prepared to be used in the 
validation process as low, medium and high QC: 
Low QC (7 µg/ml) = 21 µl of Std stock 1 µg/µl + 2979 µl of whole blood 
Medium QC (20 µg/ml) = 20 µl of Std stock 1 µg/µl + 980 µl of whole blood 
High QC (35 µg/ml) = 35 µl of Std stock 1 µg/µl + 965 µl of calf whole blood  
 
Preparation of dried blood spot 
For whole blood standards, 20 µl of whole blood was spotted immediately after preparing the 
whole blood standards. It was spotted onto a qualitative grade 1 Whatman filter paper using a 
calibrated micropipette. The blood spot was air dried at room temperature for a minimum of 3 
hours or left overnight. While spotting and drying of the blood spot, care should be taken to 
make sure that the spotted blood does not come in contact with any surface. 
For spotting patient specimens, the whole blood was spotted immediately after taking the 
blood specimen, and left to dry as above. 
 
Preparation of Internal standard for extraction from dried blood spot 
A stock solution of internal standard (IS) – Aminoacetophenone (1 µg/µl) was prepared by 
dissolving 2 mg of Aminoacetophenone pure powder in 2 ml of acetonitrile.. 
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Preparation of extraction solvent containing internal standard for extraction from dried 
blood spot 
Acetonitrile and Methanol (50%: 50%) + 10 µl of 1 µg/µl of Aminoacetophenone stock to 
make up 1 ml of the extraction mixture. 
Figure 9: Extraction of phenobarbitone from dried blood spot 
 
 
Correction of DBS phenobarbitone concentration for haematocrit value 
The percentage of plasma was calculated for both the standards and patient specimens as 
follows: 
                % Plasma = 100 – Haematocrit 
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The corrected DBS phenobarbitone concentration was calculated using the formula: 
Corrected DBS concentration = Final DBS concentration * (Standard plasma % / Patient 
plasma %) 
 
Development and validation of the assay for the extraction of 
phenobarbitone from dried blood spot  
A) Water standards – To determine the retention time of the analyte and Internal 
standard 
Water standards containing the drug – phenobarbitone and the internal standard – 
Aminoacetophenone were prepared and analysed to detect the retention time of the drug and 
the IS. 
 
B) Blank matrix specimens  
Blank specimens of dried blood spot were obtained from 10 different sources. The blank 
specimens were obtained both from patients on antiepileptics other than phenobarbitone as 
well as from patients who were not on antiepileptics, but on other drugs. 
These blank specimens were analysed for the presence of interference under the drug and the 
IS. The blank specimens were compared against the lowest standard – Std 2.5. These 
specimens were analysed to exclude interference due to the following antiepileptics – 
phenytoin, carbamazepine, valproate, oxcarbazepine, lamotrigine, levetiracetam, clonazepam, 
clobazam and topiramate. 
 
C) Non-zero dried blood spot specimens – expected concentration range 
Dried blood spot specimens from 10 different patients on phenobarbitone were prepared and 
analysed to determine an expected range in the concentrations of the study specimens. Based 
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on the analysis of these specimens the expected range of concentrations was found to be 
between 2.5 µg/ml to 40 µg/ml. 
 
D) Calibration curve - Linearity 
Calibrators (standards) were prepared by spiking whole blood with known concentrations of 
phenobarbitone. Based on the analysis of non-zero specimens, the expected range of 
concentrations in the study specimens were found to be between 2.5 µg/ml to 40 µg/ml. 
Five calibrators were prepared – 40, 30,15,5 & 2.5 µg/ml from the standard stock solution. 
The QC - 10µg/ml was prepared from a separate QC stock solution. The preparation of the 
calibrators and QC is shown in the section – (Preparation of dried blood spot standards and 
quality control, page 63 & 64).   
8 different calibration runs were performed over a span of several days using freshly prepared 
standards to ensure linearity of the standard curve.  
 
E) Recovery of analyte from the Dried Blood spot – Extraction Efficiency 
Aqueous standards and QC 
Aqueous standards were prepared using the primary and secondary standard and QC stocks. 
Primary standard stock – 1 µg/µl (prepared as mentioned in Section - Preparation of drug 
stock solution, page 56)  
Secondary standard stock – 0.1 µg/µl = 100 µl of primary Std stock 1 µg/µl + 900 µl of water 
Primary QC stock - 1 µg/µl (prepared as mentioned in Section - Preparation of drug stock 
solution page 56)  
Secondary QC stock – 0.1 µg/µl = 100 µl of primary QC stock 1 µg/µl + 900 µl of water 
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Preparation of aqueous standards and Quality Controls (QC) 
Std 40 µg/ml = 40 µl of primary Std stock + 960 µl of water 
Std 30 µg/ml = 30 µl of primary Std stock + 970 µl of water 
Std 15 µg/ml = 150 µl of secondary Std stock + 850 µl of water 
Std 5 µg/ml = 50 µl of secondary Std stock + 950 µl of water 
Std 2.5 µg/ml = 25 µl of secondary Std stock + 975 µl of water 
Two QC’s were prepared: 
QC 10 µg/ml = 100 µl of secondary QC stock + 900 µl of water 
QC 25 µg/ml = 25 µl of primary QC stock + 975 µl of water  
 
Figure 10: Extraction of aqueous standards  
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Analysis 
The aqueous standards were analysed by HPLC and the ratio of the area of drug and the IS 
was calculated. The dried blood spot calibrators and two dried blood QC’s were also 
analysed. The % recovery was calculated as follows: 
Step 1: Intercept and slope for the aqueous standard curve is calculated.  
Step 2: Using the ratios from the DBS analysis, the concentration is calculated using the 
standard curve from the aqueous standards. 
% Recovery = [Mean of (Concentration from DBS/ Known concentration)]* 100 
 
F) Intra-day variability (same batch, same day) 
On the same day, the following analyses were performed: 
Standard 2.5 µg/ml (low concentration): Extracted 5 times from a single standard and 
analysed.  
Standard 40 µg/ml (high concentration):  Extracted 5 times from a single standard and 
analysed. 
To check the intra-day reproducibility the % coefficient of variation (% CV) was calculated 
 
G) Inter-day variability (same batch, different days) 
This was assessed using 3 concentrations - low (7 µg/ml), medium (20 µg/ml) and high (35 
µg/ml).  
The preparation of the QC’s is shown in the section – (Preparation of dried blood spot 
standards and quality control, pages 63 & 64).   
Each concentration was extracted 3 times on day 1 and then another 3 extractions were 
performed on Day 3. After assay the results were compared and the % CV was calculated for 
each concentration. The extractions were from the same standards on Day 1 and Day 3. 
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H) Reproducibility of injection 
Reproducibility of injection was checked using the same high, medium and low 
concentrations as above.  Each concentration was extracted once and from this 3 repeat 
injections were made from the single extract.  
The % CV was calculated for each concentration. 
 
I) Sensitivity 
The lowest standard of phenobarbitone that was measured from dried blood spot was 2.5 
µg/ml. The chromatogram shows a clear baseline under this concentration. 
 
J) Stability 
The stability of phenobarbitone in dried blood spot were analysed at 7 days, 19 days and 26 
days.  
A set of standards and QC were freshly prepared on Day 1.  After drying, the calibration 
curve was run. Linearity was good. The Quality control specimen was run and was 
satisfactory. These DBS specimens were then placed in plastic bags and the stability was 
checked for the following conditions: 
Storage at laboratory temperatures (24 - 30° C). 
Storage and transport at (35 - 40° C).  The DBS specimens in a sealed plastic bag were driven 
around in a car for the period of stability testing.  
New standards were freshly prepared at 7 days and 26 days. At each of these time points, the 
freshly prepared standards were compared against the lab standards and the car standards to 
assess stability.  On day 19 the laboratory and car standards were compared. 
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Patient methodology 
Institutional Review Board Clearance 
The study was approved by the Institutional review board of Christian Medical College and 
Hospital, Vellore (IRB number – 8654). 
Patient population 
This was an open label, prospective study conducted in the Department of Pharmacology and 
Clinical Pharmacology, Christian Medical College, Vellore in collaboration with the 
Department of Neurology. Inclusion criteria were patients in the age group 18 to 65 years and 
receiving phenobarbitone for epilepsy. After informed consent was obtained, patients were 
recruited from the outpatient setting of the Department of Neurology. All patients who were 
prescribed phenobarbitone and who were taking it regularly were included in the study. The 
brand and the dose of phenobarbitone prescribed were based on the clinician’s discretion and 
were of no consequence to the study. The compliance to medication was confirmed prior to 
including the patient in the study. The timing of the specimen collection could be at any time 
point (and not necessarily the trough concentration), provided the patient was compliant with 
the medication. Upon inclusion in the study, each patient was given a study number. Data 
from the study was stored under the patient study number. The following demographic and 
medication details were also noted at the time of inclusion: age, sex, concomitant medications 
and dose of phenobarbitone. 
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Calculation of sample size 
The required sample size to show a relationship of phenobarbitone in serum and dried blood 
spot was found to be 74 subjects with 80% power and 5% level of significance with an 
anticipated correlation of 0.85. 
Within the time allotted for recruitment and analysis of the specimens, 36 patients were 
enrolled in the study. This dissertation presents the results of the 36 patients. The study 
continues.  
Collection of Blood and Serum Specimens 
Figure 11: Algorithm for sample collection, separation and storage                     
 36 patients were 
recruited after obtaining 
informed consent 
2ml in EDTA Tube 
1ml sent for PCV 
4ml blood collected by venipuncture 
  
  
    
  
1ml collected into an 
eppendorf 
  
20µl Blood spots created on 
Whatman filter paper using a 
repeating pipette 
  
2ml in plain tube 
  
Serum separated and 
stored at -20⁰C until 
analysis 
Phenobarbitone levels in serum 
measured by HPLC 
  
Blood spots dried and stored 
at room temperature 
Phenobarbitone levels 
in DBS measured by 
HPLC 
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Haematocrit estimation 
At the time of sample collection from the patient, 1 ml of whole blood was immediately sent 
for packed cell volume estimation (PCV) to the Department of Transfusion Medicine and 
Immunohematology. PCV was estimated by the Unicel D*H 800 coulter cellular analysis 
system. The PCV was also estimated at the time of preparation of standards for dried blood 
spot analysis. 
 
Preparation of Serum Specimen 
2 ml of whole blood was collected into a BD vacutainer plain tube and after standing to allow 
clotting the specimen was centrifuged using a doctor centrifuge at step 1 (5 step regulator) for 
3 minutes and the serum separated into clean eppendorf tubes.  
 
Preparation of dried blood spots 
For spotting patient specimens: 20 µl was spotted onto a qualitative grade 1 Whatman filter 
paper using a calibrated micropipette.  The whole blood was spotted immediately after taking 
the blood specimen, and left to dry at room temperature for a minimum of 3 hours or left 
overnight.  
 
Determination of the relevance of spotting inconsistencies 
In order to evaluate the importance of the correct technique of spotting, DBS specimens 
which were incorrectly spotted were analysed and the concentrations obtained were 
compared graphically and statistically against the corresponding serum concentrations. The 
methods employed were, precision, bias, Spearman ranked correlation, Bland-Altman plot 
and Mann Whitney-U test.  These are all outlined below. 
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Statistical analysis and graphical plots 
The following statistical analyses were applied using R program language (version 3.1.5). 
 Frequency histogram with the distribution curve overlaid – The frequency histogram 
assesses Normality of data. This is plotted with a distribution curve derived from the 
mean and the standard deviation of the data. 
 Q-Q plot compares the two distributions and matches the quantiles of one with same 
quantiles of the other. These plots reveal the location, scale difference and identity of 
the outliers. 
 The Shapiro-Wilk normality test: From the above methods, a graphical assessment 
can be made regarding normal or non-normal distribution of the data. However, the 
Shapiro’s test will give a mathematical value as to whether or not normality exists. 
 Linear Regression curves 
 Spearman rank correlation test: Used to obtain the correlation with non-parametric 
data. 
 Box plots: Graphical representations of the median and quartiles 1 and 3. 
 Sensitivity analysis: A sensitivity analysis is performed to see if an outlier skews the 
data. In sensitivity analysis, the Spearman Rank correlation test is repeated after 
removing the outlier. 
 Mann Whitney-U test:  This is a non-parametric test equivalent to paired T-test. It is 
used to compare paired data. It uses the signs and the relative magnitudes of the data 
instead of the actual data. It calculates the difference and excludes zero. It arranges 
the remaining  difference in the ascending order of magnitude, ignoring the signs and 
giving a rank  number. The Null hypothesis states that there is no difference between 
the two groups. 
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 Coefficient of variation (CV): It gives a measure of the dispersion of all the points in a 
data around the mean of the data. It is calculated as CV = (Standard deviation/ Mean) 
 Bias(% of the mean difference) = [(∑ Individual difference)/n]*100 , where,  
              Individual difference = (Predicted – Measured)/Measured 
Reference: (83) 
 Precision(% mean of absolute difference) = [(∑ Absolute of individual  
difference)/n]*100, where, 
      Absolute of individual difference = (│Predicted – Measured│)/Measured 
Reference: (83) 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
  
Results 
77 
 
2.5 5.0 7.5 10.0 12.5 15.0 min
-2500
0
2500
5000
7500
10000
12500
15000
17500
20000
22500
25000
27500
30000
uV
           IS – Ornidazole  
    (RT – 8.703 minutes) 
         Phenobarbitone  
   (RT – 14.179 minutes) 
The results are presented in tabular and graphical format. The significance of the results is 
discussed in the following section. 
 
Development of the assay for the measurement of phenobarbitone in serum 
A) Water standards 
From separate injections of the water standards, the retention times (RT) of Ornidazole 
(internal standard) and Phenobarbitone were 8.703 and 14.179 minutes respectively under the 
final standardised set of HPLC conditions. 
Figure 12: Standard 40 µg/ml chromatogram showing the IS (Ornidazole) and 
Phenobarbitone peaks under the final standardised HPLC conditions (for serum) 
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B) Blank matrix specimens 
Blank specimens from 10 different sources were analysed. The chromatogram traces of the 
blank specimens were compared against that for standard 5. No interfering peaks were seen 
under the retention times of both phenobarbitone and ornidazole. 
Inferences due to the following antiepileptics were excluded -phenytoin, carbamazepine, 
valproate, oxcarbazepine, lamotrigine, levetiracetam, clonazepam, clobazam and topiramate. 
 
Figure 13:  Chromatogram showing the blank specimens of serum compared against 
standard 5 
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Figure 13a: Magnified view of the blank specimens compared against standard 5 
              
Table 2: Retention time and area under the curve of the IS (Ornidazole) and Phenobarbitone 
under the final standardised HPLC conditions (for serum) 
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C) Non-zero specimens 
Specimens obtained from 10 different patients on phenobarbitone, were analysed to 
determine the expected range of concentrations in the study specimens. The range of 
concentrations obtained was between 2.5 to 50 µg/ml.  
Figure 14: Chromatogram showing the non-zero specimens (for serum) 
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Figure 14a: Magnified view of the non-zero specimens (for serum) 
   
D) Calibration curve 
Six calibrators – 50, 30, 20, 10, 5 & 2.5µg/ml were prepared from the standard stock solution 
and checked for linearity. The calibration curve was run 8 times. The linearity of the curve 
was maintained between 2.5 µg/ml and 50 µg/ml with a coefficient of correlation, r2 = 
0.9997. 
Table 3: Statistical data showing linearity of the calibration curve (for serum) 
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Figure 15: Linearity of the calibration curve (from 2.5 µg/ml to 50 µg/ml) 
                
 
Final hplc conditions for the measurement of phenobarbitone in serum. 
The final methodology is given in the Methodology Section on pages 55 & 56. A blank and 
standard chromatogram along with the area under the chromatogram curve and retention 
times is shown in figure 12, 13. 
 
Validation of the assay for measuring phenobarbitone concentration in 
serum 
A) Intra-day variability (same batch, same day) 
Intra - day variation of standards 50 and 5 are given in table 4.  % CV was < 2% for both 
concentrations. 
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Table 4: Intra-day variation in the analysis of phenobarbitone from serum 
   
Figure 16: Chromatogram for the Intra- day variation using standard 50 (n=5) 
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B) Inter-day variability (same batch, different days) 
The results of the analysis of the 3 extractions of high, medium and low concentrations on the 
two separate days are given in table 5.  The % CV was found to be < 4% for all three 
concentrations. 
Table 5: Inter-day variation in the analysis of phenobarbitone from serum 
                          
Figure 17: Chromatogram for the Inter-day variation using 20 µg/ml (n=3 on each day) 
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There is a small percentage shift in the retention times of the IS and the drug from day 1 to 
day 2. The % change in the retention time will be greater for an analyte which has a longer 
retention time, hence, the change in the retention time of the drug is more than that of IS.  
 
C) Reproducibility of injection 
Evaluating the reproducibility of injection by analysing 5 repeat injections of a low and high 
concentration from the same extract, the % CV was found to be < 3% for both the low and 
high concentrations as shown in the table below. 
Table 6: Reinjection reproducibility in the analysis of phenobarbitone from serum 
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Figure 18: Chromatogram showing reinjection reproducibility using Std 5 (n=5) 
 
 
Development of the assay for the measurement of phenobarbitone in dried 
blood spot 
A) Water standards 
From separate injections of the water standards, the retention times of Aminoacetophenone 
(internal standard) and Phenobarbitone were 8.007 and 19.343 minutes respectively under the 
final standardised set of HPLC conditions. 
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Figure 19: Standard 30 µg/ml chromatogram showing the IS (Aminoacetophenone) and 
Phenobarbitone peaks under the final standardised HPLC conditions (for dried blood spot) 
 
  
B) Blank matrix specimens 
Blank specimens from 10 different sources were analysed. The chromatogram traces of the 
blank specimens were compared against that for standard 2.5. No interfering peaks were seen 
under retention times for both phenobarbitone and aminoacetophenone. 
Inferences due to the following antiepileptics were excluded - phenytoin, carbamazepine, 
valproate, oxcarbazepine, lamotrigine, levetiracetam, clonazepam, clobazam and topiramate. 
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Figure 20: Chromatogram showing the blank specimens of dried blood spot compared 
against Standard 2.5 
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Table 7: Retention time and area under the curve of the IS (Aminoacetophenone) and 
Phenobarbitone under the final standardised HPLC conditions (for dried blood spot: 
 
 
 
C) Non-zero specimens 
Specimens obtained from 10 different patients on phenobarbitone were analysed to determine 
the expected range of concentrations in the study specimens. The range of concentrations 
obtained was between 2.5 µg/ml to 40 µg/ml. 
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Figure 21: Chromatogram showing the non-zero specimens (for dried blood spot) 
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D) Calibration curve 
Five calibrators – 40, 30, 15, 5 & 2.5µg/ml were prepared from the standard stock solution 
and checked for linearity. The calibration curve was run 8 times. The linearity of the curve 
was maintained between 2.5 µg/ml and 40 µg/ml with a coefficient of correlation, r2 = 
0.9973. 
Table 8 : Statistical data showing linearity of the calibration curve (for dried blood spot) 
 
 
Figure 22: Linearity of the calibration curve (from 2.5 µg/ml to 40 µg/ml) 
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E) Recovery 
The mean recovery (%) was calculated as shown in the methodology section on page 69 and 
was found to be 89.2%. 
Table 9: %  recovery of individual concentrations of phenobarbitone ( from 2.5 µg/ml to 40 
µg/ml) 
 
 
Final hplc conditions for the measurement of phenobarbitone in dried 
blood spot 
The final methodology is given in the Methodology Section on page 63. A blank and 
standard chromatogram along with the area under the chromatogram curve and retention 
times is shown in figures 19 & 20. 
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Validation of the assay for the measurement of  phenobarbitone in dried 
blood spot 
 
A) Intra-day variability (same batch, same day) 
The % CV for the high and low concentrations is given below in table 10.  The 
chromatogram is shown in Figure 23. 
Table 10: Intra-day variation in the analysis of phenobarbitone from dried blood spot 
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Figure 23: Chromatogram showing Intra-day variation using Standard 2.5 (n=5) 
 
 
 
 
 
B) Inter-day variability (same batch, different days) 
Table 11 gives the % CV for the inter - day variation of the high, medium and low 
concentrations on the two separate days.  
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Table 11: Inter-day variation in the analysis of phenobarbitone from dried blood spot 
                  
Figure 24: Chromatogram showing Inter-day variation using 20 µg/ml (n=3 on each day) 
 
C) Reproducibility of injection  
The reproducibility of injection evaluated using 3 repeat injections of a low, medium and 
high concentration, gave a % CV of < 2% for all the concentrations. 
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Table 12: Reinjection reproducibility in the analysis of phenobarbitone from dried blood spot 
                     
Figure 25: Chromatogram showing Reinjection reproducibility using 7 µg/ml (n=3) 
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D) Stability 
Phenobarbitone was found to be stable up to the 26 days tested in a DBS specimen, both 
under laboratory and simulated transport conditions. Refer table 1 – 4 under the Appendix 
section for details. 
 
Validation completed. 
The above validated assays were then applied to the measurement of phenobarbitone in the 
serum and dried blood spots of study patients. 
Study patients:   
The R – program (version 3.1.5) was used for the statistical analysis and graphical 
representations. The script for each of the relevant programs is shown under the appropriate 
heading in a box. 
1. The mean, median and Interquartile ranges for the concentration of PHB in serum 
and the DBS concentration were determined using the R-program  
 R script for the above (# signifies a comment): 
attach(Final_pts)              # This attaches the relevant file and must be performed at the 
    # start of each run.  Final_pts is the csv file with the serum  
    # concentrations and the CDBS concentrations (Refer  
                                              # Appendix – table 5) 
      summary(Final_pts) # To get a summary of the data 
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Table 13: Summary data of the study patients (n=36) 
        
 
Demographic details such as age and gender, and co-medications are shown in table 14. 
Table 14: Distribution of age, gender and concomitant medications 
 
Males Females 
Age            
(median &    
range) 
+   
PHT 
+     
PHB 
+            
Val 
+    
CBZ 
+     
LTG 
+       
LVT 
+   
Clobazam 
+    
Clonazepam 
+      
Other 
N 22 14 39  (18-61) 14 36 4 10 1 Nil 5 1 20 
 
*PHT – Phenytoin, PHB – Phenobarbitone, Val – Valproate, CBZ – Carbamazepine,           
LTG – Lamotrigine,   LVT – Levetiracetam, Other medications ( Folic acid - 9, Liv-52 - 1, 
Olanzapine - 1, Glyciphage - 1, Glimepiride - 1, Amitriptyline - 1, L-Carnitine - 1, Coenzyme 
– Q - 1, Riboflavin - 1,Salbutamol - 1, Amlodipine - 1, Aspirin - 1) 
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2. Calculate the precision and the bias between the predicted and the measured serum 
concentration. (Before and after correcting for PCV) 
From the equations shown on page 75 the following results were obtained. 
Before correcting for PCV i.e. uncorrected DBS (UDBS) - Imprecision = 10% 
Before correcting for PCV i.e. uncorrected DBS (UDBS) - Bias = 1% 
After correcting for PCV i.e. corrected DBS (CDBS) - Imprecision = 8% 
After correcting for PCV i.e. corrected DBS (CDBS) - Bias = 0.49% 
All subsequent calculations were based on CDBS 
 
3: Bland Altman Plot  
It shows the mean and standard deviation of the mean of the difference (Figure 26) 
 R script for the above (# signifies a comment): 
  attach(Final_pts) 
  # Bland-Altman plot R function (Based on the program by: jmmateos@mce.hggm.es) 
  means <- mean   # <- is a symbol meaning assign to   
  diffs <- diff 
  mdiff <- mean(diffs) 
  sddiff <- sd(diffs) 
  R Script continued on next page. 
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# Compute the figure limits 
ylimh <- mdiff + 2 * sddiff   #Upper limit on y axis is +2 standard deviations 
yliml <- mdiff - 2 * sddiff  #Lower limit on y axis is - 2 standard deviations 
# Plot data 
plot(diffs ~ means, pch=20, col="blue", main="Bland-Altman Plot",xlab="Mean of 
Measured Concentration (mg/L)", 
cex.lab=0.9, ylab ="Difference in Predicted-Measured Concentration (mg/L)", 
ylim = c(yliml-4, 12)) 
# Explanation of symbols,’ ~’ symbol means plot differences and means against each 
other, 
# pch=format for the symbol = full spot, ‘main’ is for the graph title, ‘col’ assigns a 
colour 
# xlab and ylab ares the labels for the x and y axis respectively, ylim is the full y axis. 
abline(h = mdiff,lty=4)  # Sets the centre line, lty is the line type 
abline(h=0)   # Sets a line at 0 
abline(h = mdiff + 1 * sddiff, lty = 3)   # shows a line at 1 standard deviation 
abline(h = mdiff - 1 * sddiff, lty = 3) 
abline(h = mdiff + 2 * sddiff, lty = 2)  # shows a line at 2 standard deviations 
abline(h = mdiff - 2 * sddiff, lty = 2) 
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Figure 26: Bland Altman plot showing the mean of the difference between the predicted and 
the measured serum concentrations (in study patients) 
 
From the Bland Altman plot, the mean of the difference between the predicted and the 
measured concentration was 0.81, with a standard deviation of 2.5.  
 
4: Test for normal distribution of data in the study patients 
The Q-Q plot and the histogram with the normal distribution curve based on the mean and the 
standard deviation of the data is shown below in figures 27-30.  From both the Q-Q plot and 
the histogram with the normal distribution curve, the data for serum and corrected dried 
blood spot concentrations do not appear normally distributed. 
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 R script for the above (# signifies a comment): 
attach(Final_pts)              # This attaches the relevant file 
min(Serum.Conc.)  # Find the minimum concentration 
max(Serum.Conc.)  # Find the maximum concentration 
# To plot the histogram. 
bins=seq(min(Serum.Conc.),max(Serum.Conc.)+2,2) # bins is a single bar on the  
        # histogram 
hist(Serum.Conc.,breaks=bins, main="",ylab="Frequency.", xlab="Concentration of 
Phenobarbitone in Serum (mg/L)", col="green") 
# main: main heading, ylab and xlab refer to the y and x labels, col is the colour 
# Putting in a distribution curve: 
# 1st step: Assign our histogram to h 
h<-hist(Serum.Conc.,breaks=bins,main="",ylab="Frequency",xlab="Concentration of 
Phenobarbitone in Serum (mg/L)",col="green") 
# <- this symbol means assign the statement to for example in this case the letter h 
# 2nd step:  Create 20 bins from our data – which helps define the data better. 
xfit<-seq(min(Serum.Conc.),max(Serum.Conc.),length=20) 
 
R Script continued on next page 
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# 3rd step:  Given our data mean and sd , find the normal distribution  
yfit<-dnorm(xfit,mean=mean(Serum.Conc.),,sd=sd(Serum.Conc.)) 
# 4th step:  Fit the normal distribution to our data 
yfit<-yfit*diff(h$mids[1:2])*length(Serum.Conc.) 
# 5th step:  Plot these lines lwd= line width, 1 is default, 2 is double 1 
lines(xfit,yfit,lwd=1) 
 
Figure 27: Histogram with Normal distribution curve – Serum Concentration 
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This was also performed for the Corrected dried blood spot concentration and this is shown in 
the figure below: 
Figure 28: Histogram with normal distribution curve – Corrected Dried blood spot 
concentration 
 
 
Q-Q plot 
 R script for the above (# signifies a comment): 
attach(Final_pts) 
qqnorm(Serum.Conc.,col="green")  # Code for a normal Q-Q plot: 
qqline(Serum.Conc.,col="black")  
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Figure 29: Q-Q plot of Serum Concentration 
 
This was also performed for the Corrected dried blood spot concentration and this is shown in 
the figure below. 
Figure 30: Q-Q plot of Corrected Dried blood spot concentration 
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5: The Shapiro-Wilk Normality test for statistical determination of normality 
 R script for the above (# signifies a comment): 
attach(Final_pts) 
# To test for normality, we apply the Shapiro test 
shapiro.test(Serum.Conc.) 
shapiro.test(DBS.Conc.) 
The assumption and null hypothesis for this test is that the data are normally distributed. On 
performing the test a ‘W’ value is returned.  There is a Shapiro-Wilk table which gives the p-
values corresponding to the ‘W’ value and the number of patients in the test. The W and P 
value of the Serum Concentration (SC) and the Corrected Dried blood spot Concentration 
(CDBS) obtained by the Shapiro test as given in Table 15. 
Table 15:  Results of the Shapiro-Wilk normality test 
 
Thus, from the Shapiro-Wilk normality test, it was confirmed that the data is not normally 
distributed in the serum and corrected dried blood spot. 
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 6: Regression plot and to determine the statistical regression using Spearman Rank 
Correlation Test: 
 R script for the above (# signifies a comment): 
attach(Final_pts) 
# For regression plot: 
plot(DBS.Conc.~Serum.Conc.,pch=20,col="blue",xlab="Serum Concentration (mg/L)", 
ylab=" Dried blood spot Concentration (mg/L)",main="" )     
# pch= 20 is a solid circle when plotted on a graph  
x=Serum.Conc. 
y=DBS.Conc. 
abline(lm(y~x))    #lm stands for linear model 
 
 
Regression plot of serum concentration versus corrected dried blood spot concentration.is 
shown in Figure 31. 
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Figure 31: Regression plot of serum concentration versus corrected dried blood spot 
concentration. 
 
Using the Spearman rank correlation test, which is the preferred test for non-parametric data, 
the correlation of SC and CDBS concentration, was performed.  
 R script for Spearman correlation (# signifies a comment): 
attach(Final_pts) 
cor(Serum.Conc.,DBS.Conc.,method="spearman") 
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Result:  The Spearman rank correlation between the serum and the corrected dried blood 
concentration was 0.9878. 
Spearman correlation sensitivity test result (after the removal of the outlier patient):  
ρ = 0.9867. 
 
7: Box plots showing median concentration values and outlying data points 
Data file (Final_group) configuration is shown in table 6 in the appendix.  Data must be 
grouped vertically as two groups (Serum and DBS) and a column of corresponding data in 
order for the labels to appear at the bottom of each of the groups. 
 R script for the above (# signifies a comment): 
      attach(Final_group)      # Final_group is the csv file where the data is arranged  
                                                  # vertically as two groups in one column                                                   
# Boxplot with the two (Serum Vs Corrected DBS concentration): 
boxplot(Conc.~ Group,col=c("red","green"),notch=TRUE,main="",xlab="Dried 
blood spot vs Serum",ylab="Concentration(mg/L)") 
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Figure 32: Box plot of Serum and Corrected dried blood spot concentration  
 
Conclusion: The box plot shows that the medians of the two groups are similar and there is 1 
outlier in both groups.  
8: Paired sample Mann Whitney-U test  
The paired sample Mann Whitney-U test confirmed that the null hypothesis (i.e. there is no 
difference between the serum and CDBS concentrations) should be retained. 
The result is shown in table 16: 
 R script for the above (# signifies a comment): 
 attach(Final_pts) 
# Mann Whitney U test  
wilcox.test(Serum.Conc.,DBS.Conc.,mu=0,alt="two.sided",conf.int=TRUE, 
conf.level=0.95, paired=TRUE,exact=FALSE,correct=TRUE)  
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Table 16:  Results of the Mann Whitney U test 
Null hypothesis Test p-value Decision 
There is no difference between 
the serum concentration of PHB 
and that measured in the CDBS 
Paired samples Mann 
Whitney - U test 
0.3919 
Retain the null 
hypothesis 
 
 
Determination of relevance of spotting inconsistencies 
1. The summary data of the patients used to determine the relevance of spotting  
inconsistencies (n=13) is shown in Table 17. 
Table 17: Summary data of patients used to determine the relevance of spotting inconsistencies 
I.D. Serum.Conc. DBS.Conc. 
Difference 
between 
DBS & 
Serum 
Mean 
Mean    19.68 20.49 0.8103 20.09 
Median   17.13 16.29 -0.035 16.72 
Minimum  2.41 2.2 -2.69 2.3 
Maximum 58.14 63.36 7.59 60 
1st Quarter 10.15 10.24 -0.7 10.21 
3rd Quarter 28.67 28.98 1.53 29.15 
     
2. The imprecision and bias between the measured and predicted serum concentration was 
found to be 18.61% and 17.20% respectively. 
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3. The Bland Altman plot, Figure 33, shows that there is a large positive bias. The mean of 
the difference between the predicted and the measured serum concentration was 3.44 with a 
standard deviation of 3.17.  
Figure 33: Bland Altman plot - spotting inconsistency (n=13) 
 
4. Regression plot and determination of statistical regression  
The statistical regression determined using the Spearman correlation test was found to be 
0.9340.   
The regression plot is shown in figure 34. 
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Figure 34: Regression plot of serum vs corrected dried blood spot concentration in 
specimens used to determine the relevance of spotting inconsistencies 
 
5.  An independent Mann Whitney U test showed that there is a significant difference 
between the serum and the corrected dried blood spot concentrations in this group of patients. 
This is shown in table 18. 
Table 18: Results of Mann Whitney-U test 
Null hypothesis Test p-value Decision 
There is no difference    
between the serum 
concentration of PHB 
and that measured in the 
CDBS 
Paired samples Mann 
Whitney U test 
0.0033 
The null hypothesis is 
discarded 
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Discussion 
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Phenobarbitone is a widely used antiepileptic used in the treatment of seizures (21). 
Therapeutic drug monitoring of phenobarbitone has been recommended for optimizing drug 
treatment (26,58). The conventional serum or plasma specimens used to monitor 
phenobarbitone concentrations pose the problems of requiring a cold chain facility for the 
specimens to be transported as well as increased risk of biohazard to handlers. Dried blood 
specimens provide a safer (69,75) and a cheaper alternative to small hospitals to send 
specimens for phenobarbitone monitoring.  
The HPLC assays required for the measurement of phenobarbitone in serum and dried blood 
spot were both developed and validated in our laboratory. Both the assays were simple 
precipitation extractions and showed good sensitivity, specificity, reproducibility and 
precision. The calibration curve for serum was linear from 2.5 to 50 µg/ml. The intra-day and 
inter-day variation in the assay expressed as % CV was less than 2% and less than 4% 
respectively for concentrations across the calibration curve. The % CV in repeat injections 
was less than 3% and the lowest concentration that was quantified with a discrete peak and an 
area more than 5 times that of a blank specimen was 2.5 µg/ml. Since it is well known that 
phenobarbitone is stable in serum/ plasma for a period of upto 4 weeks at – 20 °C (81,82), we 
did not evaluate this.  
The linearity of the calibration curve for dried blood spot ranged from 2.5 to 40 µg/ml. The 
intra-day and inter-day precision of the assay expressed as % CV was less than 9% and less 
than 7% respectively. The % CV in the repeatability of injections was less than 3% and the 
assay showed a good recovery of 89.2%. Since the local temperature varies from place to 
place and because the DBS specimens once spotted will be sent by mail for analysis to the 
TDM centres, we evaluated the stability of DBS specimens under varying temperatures. 
Stability was tested at laboratory temperatures (24 -30 °C) and simulated transport conditions 
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(35 – 40 °C). Transport was simulated by storing the papers in a car and transporting them 
over a period of 26 days. The results showed that the stability of the DBS specimens was 
retained for this period of 26 days when stored in both the laboratory and the car. 
Since the protein saver #903 card, which is normally used for spotting the whole blood, is 
expensive and this assay is primarily aimed for use in rural hospitals and poorer population,   
we used the standard Whatman filter paper for the dried blood spot analysis. Because this 
paper is not standardized for width, the whole blood spot which contains a known volume of 
blood (20 µl), was cut out and used for extraction.  Due to the disadvantages of the finger 
prick method (as mentioned in pages 44 & 45), we employed the second method of spotting 
blood using a calibrated micropipette.  
This was an open label, prospective study where the serum and dried blood spot specimens of 
36 patients who were on phenobarbitone, were analysed and the concentrations compared. 
The imprecision and bias between the measured and the predicted serum concentrations of 
phenobarbitone was found to be higher when the DBS concentration was uncorrected for 
PCV (UDBS), than when corrected for PCV (CDBS). Thus analysis was done with the CDBS 
concentrations.   
The graphical and statistical methods demonstrated that the data in both the groups (serum 
concentration and CDBS concentration) were not normally distributed. Non-parametric tests 
were therefore used for analysis. The Spearman rank correlation test showed a good 
correlation between the concentration of phenobarbitone in serum and the corrected dried 
blood spot (ρ = 0.9878). A box plot of the two groups showed 1 outlier in each of the groups. 
This could be identified as patient XXXX. Sensitivity analysis was performed by removing 
the outlier and this showed that this patient had no significant effect on the data as the 
correlation was maintained (ρ = 0.9867). Our study showed a very good correlation between 
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the serum and the CDBS concentrations which agrees with La Marca et al (74). The Mann 
Whitney-U test confirmed that there was no difference between the measured concentration 
in serum and that in the dried blood spot (p = 0.3919).  Since the therapeutic range of 
phenobarbitone has been established for serum/ plasma, it is necessary to determine a 
serum/plasma concentration.  However, due to the Mann Whitney test confirming that there 
is no statistical difference between the two groups we can use the PHB concentration in the 
DBS as the predictive measure of PHB in the serum without having to employ an equation to 
relate the two.  A possible reason for the agreement in the concentration of PHB between the 
two groups could be the low protein binding of the phenobarbitone (40 – 60%).  
The Bland Altman plot showed a small overall positive bias.   However, it does seem to 
indicate a trend which may have to be considered for concentrations above 30 µg/ml. The 
numbers of specimens in this study with concentrations over 30 µg/ml was only 7, out of 
which only 3 had a % difference ([(serum concn – CDBS concn)/serum] * 100) of more than 
10% and only 1 more that 20%.  In only 2 of the patients would this result have possibly 
caused an incorrect change in dose as the measured serum concentrations were 38.4 µg/ml 
and 34 µg/ml respectively with the corresponding CDBS concentrations of 45.9 µg/ml and 
41.5 µg/ml. More work needs to be done, to determine if this is a true effect and if so what 
correction, if any, needs to be applied.  
Spotting inconsistencies were seen during the spotting process when a different volume of 
blood remained in the tip after the blood had been delivered to the filter paper.  When the 
degree to which these inconsistencies are important was evaluated, it became clear from the 
results (precision, bias and the Mann Whitney-U test) that there is a highly significant 
difference between the predicted and the measured serum concentrations (p=0.0033). The 
Bland Altman plot (page 112) also showed a much higher positive bias with the mean of the 
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difference between the predicted and measured serum concentrations as 3.44 ± 3.17.  This 
highlights the importance of correctly spotting the specimens. 
Limitations of the study/assay/DBS spotting technique 
 The DBS assay had a long run time of 21 minutes since the drug – phenobarbitone 
had a long retention time. (RT= 19.343 minutes, under the final standardized HPLC 
conditions).  
Phenytoin and carbamazepine elutes even later than phenobarbitone under the final 
standardized HPLC conditions of both the serum and DBS assays. Hence, patients on 
these drugs had to be given a longer run time to prevent the carryover in the next run. 
 The spotting of the DBS specimens requires technical precision. Hence, the personnel 
performing the DBS spotting have to be adequately trained. 
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The concentration of phenobarbitone in serum can be accurately predicted from that 
measured in DBS without the need of an equation. The dried blood spot is a valid alternative 
to using serum or plasma for the measurement of phenobarbitone concentration. Thus, a 
cheaper and a safer means for TDM of phenobarbitone can be made available to the smaller 
and rural hospitals in India.  
More research needs to be carried out in evaluating the bias involved in interpreting CDBS 
concentrations above 30 µg/ml. 
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Figure 1: Extraction of Phenobarbitone from DBS 
Figure 2: Extraction of phenobarbitone from serum 
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Table 5: Format of CSV file data used for analysis using R program (for all statistical test 
except Box plot)  
File name – Final_pts 
 
 
 
 
 
 
 
 
 
Table 6: Format of CSV file data used for Box plot 
File name – Final_group 
 
 
 
I.D. Serum.Conc. DBS.Conc. 
Difference 
between 
DBS and 
serum 
conc. 
Mean of 
the DBS 
and serum 
conc. 
F1 31.14 32.56 1.42 31.85 
F2 12.97 14.17 1.20 13.57 
F3 9.87 9.39 -0.49 9.63 
Group Conc. 
Serum 31.14 
Serum 12.97 
Serum 9.87 
DBS 32.56 
DBS 14.17 
DBS 9.39 
